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Preamble
It is important that the medical profession play a signiﬁ-
cant role in critically evaluating the use of diagnostic pro-
cedures and therapies as they are introduced and tested in
the detection, management, or prevention of disease
states. Rigorous and expert analysis of the available data
documenting absolute and relative beneﬁts and risks of
those procedures and therapies can produce helpful guide-
lines that improve the effectiveness of care, optimize
patient outcomes, and favorably affect the overall cost
of care by focusing resources on the most effective
strategies.
The American College of Cardiology Foundation (ACCF)
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task Force
on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardio-
vascular diseases and procedures, directs this effort. The
Task Force is pleased to have this guideline developed in
conjunction with the European Society of Cardiology (ESC).
Writing committees are charged with the task of performing
an assessment of the evidence and acting as an independent
group of authors to develop or update written recommen-
dations for clinical practice.
Experts in the subject under consideration have been
selected from all 3 organizations to examine subject-speciﬁc
data and to write guidelines. The process includes additional
representatives from other medical practitioner and speci-
alty groups when appropriate. Writing committees are
speciﬁcally charged to perform a formal literature review,
weigh the strength of evidence for or against a particular
treatment or procedure, and include estimates of expected
health outcomes where data exist. Patient-speciﬁc modi-
ﬁers, comorbidities, and issues of patient preference that
might inﬂuence the choice of particular tests or therapies
are considered as well as frequency of follow-up and
cost-effectiveness. When available, information from
studies on cost will be considered; however, review of
data on efﬁcacy and clinical outcomes will constitute the
primary basis for preparing recommendations in these
guidelines.
The ACC/AHA Task Force on Practice Guidelines and the
ESC Committee for Practice Guidelines make every effort
to avoid any actual, potential, or perceived conﬂict of
interest that might arise as a result of an outside relation-
ship or personal interest of the Writing Committee.
Speciﬁcally, all members of the Writing Committee and
peer reviewers of the document are asked to provide dis-
closure statements of all such relationships that might be
perceived as real or potential conﬂicts of interest. Writing
Committee members are also strongly encouraged to
declare a previous relationship with industry that might be
perceived as relevant to guideline development. If a
Writing Committee member develops a new relationship
with industry during his or her tenure, he or she is required
to notify guideline staff in writing. The continued partici-
pation of the Writing Committee member will be reviewed.
These statements are reviewed by the parent Task Force,
reported orally to all members of the Writing Committee
at each meeting, and updated and reviewed by the Writing
Committee as changes occur. Please refer to the method-
ology manuals for further description of the policies used
in guideline development, including relationships with
industry, available on the ACC, AHA, and ESC World
Wide Web sites (http://www.acc.org/clinical/manual/
manual_introltr.htm, http://circ.ahajournals.org/manual/
and http://www.escardio.org/knowledge/guidelines/Rules/).
Please see Appendix I for author relationships with industry
and Appendix II for peer reviewer relationships with industry
that are pertinent to these guidelines.
These practice guidelines are intended to assist health-
care providers in clinical decision making by describing a
range of generally acceptable approaches for the diagnosis,
management, and prevention of speciﬁc diseases and con-
ditions. These guidelines attempt to deﬁne practices that
meet the needs of most patients in most circumstances.
These guideline recommendations reﬂect a consensus of
expert opinion after a thorough review of the available,
current scientiﬁc evidence and are intended to improve
patient care. If these guidelines are used as the basis for
regulatory/payer decisions, the ultimate goal is quality of
care and serving the patient’s best interests. The ultimate
judgment regarding care of a particular patient must be
made by the healthcare provider and the patient in light
of all of the circumstances presented by that patient.
There are circumstances in which deviations from these
guidelines are appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and the ESC Committee
for Practice Guidelines and will be considered current
unless they are updated, revised, or sunsetted and with-
drawn from distribution. The executive summary and rec-
ommendations are published in the August 15, 2006, issue
of the Journal of the American College of Cardiology,
August 15, 2006, issue of Circulation, and August 16, 2006,
issue of the European Heart Journal. The full-text guidelines
are e-published in the same issues of the Journal of the
American College of Cardiology and Circulation, published
in September 9, 2006, issue of Europace, as well as posted
on the ACC (www.acc.org), AHA (www.americanheart.org),
and ESC (www.escardio.org) World Wide Web sites. Copies
of the full text and the executive summary are available
from all 3 organizations.
Sidney C. Smith, Jr., MD, FACC, FAHA, FESC, Chair, ACC/
AHA Task Force on Practice Guidelines
Silvia G. Priori, MD, PhD, FESC, Chair, ESC Committee for
Practice Guidelines
ACC/AHA/ESC Guidelines 1981
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I. Introduction
A. Organization of committee and evidence review
Atrial ﬁbrillation (AF) is the most common sustained cardiac
rhythm disturbance, increasing in prevalence with age. AF
is often associated with structural heart disease, although a
substantial proportion of patients with AF have no detectable
heart disease. Hemodynamic impairment and thrombo-
embolic events related to AF result in signiﬁcant morbidity,
mortality, and cost. Accordingly, the American College of
Cardiology (ACC), the American Heart Association (AHA),
and the European Society of Cardiology (ESC) created a com-
mittee to establish guidelines for optimum management of
this frequent and complex arrhythmia.
The committee was composed of representatives of the
ACC, AHA, ESC, the European Heart Rhythm Association
(EHRA), and the Heart Rhythm Society (HRS). The document
was reviewed by reviewers nominated by these organiz-
ations and will be reviewed annually by the Task Force and
considered current unless the Task Force revises or with-
draws it from distribution.
The ACC/AHA/ESC Writing Committee to Revise the 2001
Guidelines for the Management of Patients With Atrial
Fibrillation conducted a comprehensive review of the rel-
evant literature from 2001 to 2006 using the PubMed/
MEDLINE and Cochrane Library databases. Searches
focused on English-language sources and studies in human
subjects. Articles related to animal experimentation were
cited when important to understanding concepts pertinent
to patient management.
Classiﬁcation of recommendations
. Class I: Conditions for which there is evidence and/or
general agreement that a given procedure/therapy is ben-
eﬁcial, useful, and effective.
. Class II: Conditions for which there is conﬂicting evidence
and/or a divergence of opinion about the usefulness/efﬁ-
cacy of performing the procedure/therapy.
* Class IIa: Weight of evidence/opinion is in favor of use-
fulness/efﬁcacy.
* Class IIb: Usefulness/efﬁcacy is less well established by
evidence/opinion.
. Class III: Conditions for which there is evidence and/or
general agreement that a procedure/therapy is not
useful or effective and in some cases may be harmful.
Level of evidence
The weight of evidence was ranked from highest (A) to
lowest (C), as follows:
. Level of Evidence A: Data derived from multiple random-
ized clinical trials or meta-analyses.
. Level of Evidence B: Data derived from a single random-
ized trial, or nonrandomized studies.
. Level of Evidence C: Only consensus opinion of experts,
case studies, or standard-of-care.
B. Changes since the initial publication of these
guidelines in 2001
The Writing Committee considered evidence published since
2001 and drafted revised recommendations to incorporate
results from major clinical trials such as those that
compared rhythm control and rate control approaches to
long-term management. The text has been reorganized to
reﬂect the implications for patient care, beginning with rec-
ognition of AF and its pathogenesis and the general priorities
of rate control, prevention of thromboembolism, and
methods available for use in selected patients to correct
the arrhythmia and maintain normal sinus rhythm.
Advances in catheter-based ablation technologies are
incorporated in expanded sections and recommendations,
with the recognition that such vital details as patient
selection, optimum catheter positioning, absolute rates of
treatment success, and the frequency of complications
remain incompletely deﬁned. Sections on drug therapy
have been conﬁned to human studies with compounds
approved for clinical use in North America and/or
Europe. As data on the management of patients prone to
AF in special circumstances are more robust, recommen-
dations are based on a higher level of evidence than in
the ﬁrst edition of these guidelines. Every effort was
made to maintain consistency with other ACC/AHA and
ESC practice guidelines.
C. Recommendations for management of patients
with atrial ﬁbrillation
Classiﬁcation of Recommendations and Level of Evidence
are expressed in the ACC/AHA/ESC format as follows and
described in Table 1. Recommendations are evidence
based and derived primarily from published data. The
reader is referred to the full-text guidelines for a complete
description of the rationale and evidence supporting these
recommendations.
Recommendations
1. Pharmacological rate control during atrial ﬁbrillation
Class I
(1) Measurement of the heart rate at rest and control
of the rate using pharmacological agents (either a
beta blocker or nondihydropyridine calcium channel
antagonist, in most cases) are recommended for
patients with persistent or permanent AF. (Level of
Evidence: B)
(2) In the absence of preexcitation, intravenous adminis-
tration of beta blockers (esmolol, metoprolol, or propra-
nolol) or nondihydropyridine calcium channel antagonists
(verapamil, diltiazem) is recommended to slow the ven-
tricular response to AF in the acute setting, exercising
caution in patients with hypotension or heart failure
(HF). (Level of Evidence: B)
(3) Intravenous administration of digoxin or amiodarone is
recommended to control the heart rate in patients
with AF and HF who do not have an accessory
pathway. (Level of Evidence: B)
(4) In patients who experience symptoms related to AF
during activity, the adequacy of heart rate control
should be assessed during exercise, adjusting pharmaco-
logical treatment as necessary to keep the rate in the
physiological range. (Level of Evidence: C)
(5) Digoxin is effective following oral administration to control
the heart rate at rest in patients with AF and is indicated
for patients with HF, left ventricular (LV) dysfunction, or
for sedentary individuals. (Level of Evidence: C)
1982 ACC/AHA/ESC Guidelines
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Table 1 Applying classiﬁcation of recommendations and level of evidenceb
A
C
C
/A
H
A
/ESC
G
uid
elines
1983
Downloaded from https://academic.oup.com/eurheartj/article-abstract/27/16/1979/408863
by guest
on 02 April 2018
Class IIa
(1) A combination of digoxin and either a beta blocker or
nondihydropyridine calcium channel antagonist is
reasonable to control the heart rate both at rest and
during exercise in patients with AF. The choice of medi-
cation should be individualized and the dose modulated
to avoid bradycardia. (Level of Evidence: B)
(2) It is reasonable to use ablation of the AV node or acces-
sory pathway to control heart rate when pharmacologi-
cal therapy is insufﬁcient or associated with side
effects. (Level of Evidence: B)
(3) Intravenous amiodarone can be useful to control the
heart rate in patients with AF when other measures are
unsuccessful or contraindicated. (Level of Evidence: C)
(4) When electrical cardioversion is not necessary in
patients with AF and an accessory pathway, intravenous
procainamide or ibutilide is a reasonable alternative.
(Level of Evidence: C)
Class IIb
(1) When the ventricular rate cannot be adequately con-
trolled both at rest and during exercise in patients
with AF using a beta blocker, nondihydropyridine
calcium channel antagonist, or digoxin, alone or in com-
bination, oral amiodarone may be administered to
control the heart rate. (Level of Evidence: C)
(2) Intravenous procainamide, disopyramide, ibutilide, or
amiodarone may be considered for hemodynamically
stable patients with AF involving conduction over an
accessory pathway. (Level of Evidence: B)
(3) When the rate cannot be controlled with pharmacologi-
cal agents or tachycardia-mediated cardiomyopathy is
suspected, catheter-directed ablation of the AV node
may be considered in patients with AF to control the
heart rate. (Level of Evidence: C)
Class III
(1) Digitalis should not be used as the sole agent to control
the rate of ventricular response in patients with parox-
ysmal AF. (Level of Evidence: B)
(2) Catheter ablation of the AV node should not be
attempted without a prior trial of medication to
control the ventricular rate in patients with AF. (Level
of Evidence: C)
(3) In patients with decompensated HF and AF, intravenous
administration of a nondihydropyridine calcium channel
antagonist may exacerbate hemodynamic compromise
and is not recommended. (Level of Evidence: C)
(4) Intravenous administration of digitalis glycosides or non-
dihydropyridine calcium channel antagonists to patients
with AF and a preexcitation syndrome may paradoxically
accelerate the ventricular response and is not rec-
ommended. (Level of Evidence: C)
2. Preventing thromboembolism
(For recommendations regarding antithrombotic therapy in
patients with AF undergoing cardioversion, see Section
I.C.3.d.)
Class I
(1) Antithrombotic therapy to prevent thromboembolism is
recommended for all patients with AF, except those
with lone AF or contraindications. (Level of Evidence: A)
(2) The selection of the antithrombotic agent should be
based upon the absolute risks of stroke and bleeding
and the relative risk and beneﬁt for a given patient.
(Level of Evidence: A)
(3) For patients without mechanical heart valves at high risk
of stroke, chronic oral anticoagulant therapy with a
vitamin K antagonist is recommended in a dose adjusted
to achieve the target intensity international normalized
ratio (INR) of 2.0 to 3.0, unless contraindicated. Factors
associated with highest risk for stroke in patients with
AF are prior thromboembolism (stroke, transient
ischemic attack [TIA], or systemic embolism) and rheu-
matic mitral stenosis. (Level of Evidence: A)
(4) Anticoagulation with a vitamin K antagonist is rec-
ommended for patients with more than 1 moderate
risk factor. Such factors include age 75 y or greater,
hypertension, HF, impaired LV systolic function (ejection
fraction 35% or less or fractional shortening less than
25%), and diabetes mellitus. (Level of Evidence: A)
(5) INR should be determined at least weekly during
initiation of therapy and monthly when anticoagulation
is stable. (Level of Evidence: A)
(6) Aspirin, 81–325 mg daily, is recommended as an alterna-
tive to vitamin K antagonists in low-risk patients or in
those with contraindications to oral anticoagulation.
(Level of Evidence: A)
(7) For patients with AF who have mechanical heart valves,
the target intensity of anticoagulation should be based
on the type of prosthesis, maintaining an INR of at
least 2.5. (Level of Evidence: B)
(8) Antithrombotic therapy is recommended for patients
with atrial ﬂutter as for those with AF. (Level of
Evidence: C)
Class IIa
(1) For primary prevention of thromboembolism in patients
with nonvalvular AF who have just 1 of the following
validated risk factors, antithrombotic therapy with
either aspirin or a vitamin K antagonist is reasonable,
based upon an assessment of the risk of bleeding compli-
cations, ability to safely sustain adjusted chronic anti-
coagulation, and patient preferences: age greater than
or equal to 75 y (especially in female patients), hyper-
tension, HF, impaired LV function, or diabetes mellitus.
(Level of Evidence: A)
(2) For patients with nonvalvular AF who have 1 or more of
the following less well-validated risk factors, antithrom-
botic therapy with either aspirin or a vitamin K antagon-
ist is reasonable for prevention of thromboembolism:
age 65 to 74 y, female gender, or CAD. The choice
of agent should be based upon the risk of bleeding
complications, ability to safely sustain adjusted
chronic anticoagulation, and patient preferences.
(Level of Evidence: B)
(3) It is reasonable to select antithrombotic therapy using
the same criteria irrespective of the pattern (i.e., par-
oxysmal, persistent, or permanent) of AF. (Level of
Evidence: B)
(4) In patients with AF who do not have mechanical prosthe-
tic heart valves, it is reasonable to interrupt anticoagu-
lation for up to 1 wk without substituting heparin for
surgical or diagnostic procedures that carry a risk of
bleeding. (Level of Evidence: C)
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(5) It is reasonable to reevaluate the need for anticoagula-
tion at regular intervals. (Level of Evidence: C)
Class IIb
(1) In patients 75 y of age and older at increased risk of
bleeding but without frank contraindications to oral
anticoagulant therapy, and in other patients with mod-
erate risk factors for thromboembolism who are unable
to safely tolerate anticoagulation at the standard inten-
sity of INR 2.0 to 3.0, a lower INR target of 2.0 (range 1.6
to 2.5) may be considered for primary prevention of
ischemic stroke and systemic embolism. (Level of
Evidence: C)
(2) When surgical procedures require interruption of oral
anticoagulant therapy for longer than 1 wk in high-risk
patients, unfractionated heparin may be administered
or low-molecular-weight heparin given by subcutaneous
injection, although the efﬁcacy of these alternatives in
this situation is uncertain. (Level of Evidence: C)
(3) Following percutaneous coronary intervention or revas-
cularization surgery in patients with AF, low-dose
aspirin (less than 100 mg per d) and/or clopidogrel
(75 mg per d) may be given concurrently with anticoagu-
lation to prevent myocardial ischemic events, but these
strategies have not been thoroughly evaluated and are
associated with an increased risk of bleeding. (Level of
Evidence: C)
(4) In patients undergoing percutaneous coronary interven-
tion, anticoagulation may be interrupted to prevent
bleeding at the site of peripheral arterial puncture,
but the vitamin K antagonist should be resumed as
soon as possible after the procedure and the dose
adjusted to achieve an INR in the therapeutic range.
Aspirin may be given temporarily during the hiatus,
but the maintenance regimen should then consist of
the combination of clopidogrel, 75 mg daily, plus war-
farin (INR 2.0 to 3.0). Clopidogrel should be given for a
minimum of 1 mo after implantation of a bare metal
stent, at least 3 mo for a sirolimus-eluting stent, at
least 6 mo for a paclitaxel-eluting stent, and 12 mo or
longer in selected patients, following which warfarin
may be continued as monotherapy in the absence of a
subsequent coronary event. When warfarin is given in
combination with clopidogrel or low-dose aspirin, the
dose intensity must be carefully regulated. (Level of
Evidence: C)
(5) In patients with AF younger than 60 y without heart
disease or risk factors for thromboembolism (lone AF),
the risk of thromboembolism is low without treatment
and the effectiveness of aspirin for primary prevention
of stroke relative to the risk of bleeding has not been
established. (Level of Evidence: C)
(6) In patients with AF who sustain ischemic stroke or sys-
temic embolism during treatment with low-intensity
anticoagulation (INR 2.0 to 3.0), rather than add an anti-
platelet agent, it may be reasonable to raise the inten-
sity of the anticoagulation to a maximum target INR of
3.0 to 3.5. (Level of Evidence: C)
Class III
Long-term anticoagulation with a vitamin K antagonist is
not recommended for primary prevention of stroke in
patients below the age of 60 y without heart disease (lone
AF) or any risk factors for thromboembolism. (Level of
Evidence: C)
3. Cardioversion of atrial ﬁbrillation
a. Pharmacological cardioversion
Class I
Administration of ﬂecainide, dofetilide, propafenone, or
ibutilide is recommended for pharmacological cardioversion
of AF. (Level of Evidence: A)
Class IIa
(1) Administration of amiodarone is a reasonable option
for pharmacological cardioversion of AF. (Level of
Evidence: A)
(2) A single oral bolus dose of propafenone or ﬂecainide
(‘pill-in-the-pocket’) can be administered to terminate
persistent AF outside the hospital once treatment has
proved safe in hospital for selected patients without
sinus or AV node dysfunction, bundle-branch block,
QT-interval prolongation, the Brugada syndrome, or
structural heart disease. Before antiarrhythmic medi-
cation is initiated, a beta blocker or nondihydropyridine
calcium channel antagonist should be given to prevent
rapid AV conduction in the event atrial ﬂutter occurs.
(Level of Evidence: C)
(3) Administration of amiodarone can be beneﬁcial on an
outpatient basis in patients with paroxysmal or persist-
ent AF when rapid restoration of sinus rhythm is not
deemed necessary. (Level of Evidence: C)
Class IIb
Administration of quinidine or procainamide might be
considered for pharmacological cardioversion of AF, but
the usefulness of these agents is not well established.
(Level of Evidence: C)
Class III
(1) Digoxin and sotalol may be harmful when used for
pharmacological cardioversion of AF and are not rec-
ommended. (Level of Evidence: A)
(2) Quinidine, procainamide, disopyramide, and dofetilide
should not be started out of hospital for conversion of
AF to sinus rhythm. (Level of Evidence: B)
b. Direct-current cardioversion
Class I
(1) When a rapid ventricular response does not respond
promptly to pharmacological measures for patients
with AF with ongoing myocardial ischemia, symptomatic
hypotension, angina, or HF, immediate R-wave synchro-
nized direct-current cardioversion is recommended.
(Level of Evidence: C)
(2) Immediate direct-current cardioversion is recommended
for patients with AF involving preexcitation when very
rapid tachycardia or hemodynamic instability occurs.
(Level of Evidence: B)
(3) Cardioversion is recommended in patients without
hemodynamic instability when symptoms of AF are
unacceptable to the patient. In case of early relapse
of AF after cardioversion, repeated direct-current cardio-
version attempts may be made following administration
of antiarrhythmic medication. (Level of Evidence: C)
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Class IIa
(1) Direct-current cardioversion can be useful to restore
sinus rhythm as part of a long-term management strat-
egy for patients with AF. (Level of Evidence: B)
(2) Patient preference is a reasonable consideration in the
selection of infrequently repeated cardioversions for
the management of symptomatic or recurrent AF.
(Level of Evidence: C)
Class III
(1) Frequent repetition of direct-current cardioversion is not
recommended for patients who have relatively short
periods of sinus rhythm between relapses of AF after
multiple cardioversion procedures despite prophylactic
antiarrhythmic drug therapy. (Level of Evidence: C)
(2) Electrical cardioversion is contraindicated in patients
with digitalis toxicity or hypokalemia. (Level of
Evidence: C)
c. Pharmacological enhancement of direct-current
cardioversion
Class IIa
(1) Pretreatment with amiodarone, ﬂecainide, ibutilide,
propafenone, or sotalol can be useful to enhance the
success of direct-current cardioversion and prevent
recurrent AF. (Level of Evidence: B)
(2) In patients who relapse to AF after successful cardiover-
sion, it can be useful to repeat the procedure following
prophylactic administration of antiarrhythmic medi-
cation. (Level of Evidence: C)
Class IIb
(1) For patients with persistent AF, administration of beta
blockers, disopyramide, diltiazem, dofetilide, procaina-
mide, or verapamil may be considered, although the
efﬁcacy of these agents to enhance the success of
direct-current cardioversion or to prevent early recur-
rence of AF is uncertain. (Level of Evidence: C)
(2) Out-of-hospital initiation of antiarrhythmic medications
may be considered in patients without heart disease to
enhance the success of cardioversion of AF. (Level of
Evidence: C)
(3) Out-of-hospital administration of antiarrhythmic medi-
cations may be considered to enhance the success of
cardioversion of AF in patients with certain forms of
heart disease once the safety of the drug has been ver-
iﬁed for the patient. (Level of Evidence: C)
d. Prevention of thromboembolism in patients with atrial
ﬁbrillation undergoing cardioversion
Class I
(1) For patients with AF of 48-h duration or longer, or when
the duration of AF is unknown, anticoagulation (INR 2.0
to 3.0) is recommended for at least 3 wk prior to and 4
wk after cardioversion, regardless of the method (elec-
trical or pharmacological) used to restore sinus rhythm.
(Level of Evidence: B)
(2) For patients with AF of more than 48-h duration requir-
ing immediate cardioversion because of hemodynamic
instability, heparin should be administered concurrently
(unless contraindicated) by an initial intravenous bolus
injection followed by a continuous infusion in a dose
adjusted to prolong the activated partial thromboplastin
time to 1.5 to 2 times the reference control value.
Thereafter, oral anticoagulation (INR 2.0 to 3.0) should
be provided for at least 4 wk, as for patients undergoing
elective cardioversion. Limited data support subcu-
taneous administration of low-molecular-weight
heparin in this indication. (Level of Evidence: C)
(3) For patients with AF of less than 48-h duration associ-
ated with hemodynamic instability (angina pectoris,
myocardial infarction [MI], shock, or pulmonary
edema), cardioversion should be performed immedi-
ately without delay for prior initiation of anticoagula-
tion. (Level of Evidence: C)
Class IIa
(1) During the 48 h after onset of AF, the need for anticoa-
gulation before and after cardioversion may be based
on the patient’s risk of thromboembolism. (Level of
Evidence: C)
(2) As an alternative to anticoagulation prior to cardiover-
sion of AF, it is reasonable to perform transesophageal
echocardiography (TEE) in search of thrombus in the
left atrium (LA) or left atrial appendage (LAA). (Level
of Evidence: B)
(2a) For patients with no identiﬁable thrombus, cardiover-
sion is reasonable immediately after anticoagulation
with unfractionated heparin (e.g., initiated by intrave-
nous bolus injection and an infusion continued at a
dose adjusted to prolong the activated partial throm-
boplastin time to 1.5 to 2 times the control value
until oral anticoagulation has been established with
an oral vitamin K antagonist (e.g., warfarin) as evi-
denced by an INR equal to or greater than 2.0).
(Level of Evidence: B) Thereafter, continuation of oral
anticoagulation (INR 2.0 to 3.0) is reasonable for a total
anticoagulation period of at least 4 wk, as for patients
undergoing elective cardioversion. (Level of Evidence:
B) Limited data are available to support the subcu-
taneous administration of a low-molecular-weight
heparin in this indication. (Level of Evidence: C)
(2b) For patients in whom thrombus is identiﬁed by TEE,
oral anticoagulation (INR 2.0 to 3.0) is reasonable for
at least 3 wk prior to and 4 wk after restoration of sinus
rhythm, and a longer period of anticoagulation may
be appropriate even after apparently successful cardio-
version, because the risk of thromboembolism often
remains elevated in such cases. (Level of Evidence: C)
(3) For patients with atrial ﬂutter undergoing cardiover-
sion, anticoagulation can be beneﬁcial according to
the recommendations as for patients with AF. (Level
of Evidence: C)
4. Maintenance of sinus rhythm
Class I
Before initiating antiarrhythmic drug therapy, treatment
of precipitating or reversible causes of AF is recommended.
(Level of Evidence: C)
Class IIa
(1) Pharmacological therapy can be useful in patients with
AF to maintain sinus rhythm and prevent tachycardia-
induced cardiomyopathy. (Level of Evidence: C)
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(2) Infrequent, well-tolerated recurrence of AF is reason-
able as a successful outcome of antiarrhythmic drug
therapy. (Level of Evidence: C)
(3) Outpatient initiation of antiarrhythmic drug therapy is
reasonable in patients with AF who have no associated
heart disease when the agent is well tolerated. (Level
of Evidence: C)
(4) In patients with lone AF without structural heart
disease, initiation of propafenone or ﬂecainide can be
beneﬁcial on an outpatient basis in patients with parox-
ysmal AF who are in sinus rhythm at the time of drug
initiation. (Level of Evidence: B)
(5) Sotalol can be beneﬁcial in outpatients in sinus rhythm
with little or no heart disease, prone to paroxysmal AF,
if the baseline uncorrected QT interval is less than
460 ms, serum electrolytes are normal, and risk factors
associated with class III drug-related proarrhythmia are
not present. (Level of Evidence: C)
(6) Catheter ablation is a reasonable alternative to pharma-
cological therapy to prevent recurrent AF in sympto-
matic patients with little or no LA enlargement. (Level
of Evidence: C)
Class III
(1) Antiarrhythmic therapy with a particular drug is not rec-
ommended for maintenance of sinus rhythm in patients
with AF who have well-deﬁned risk factors for proar-
rhythmia with that agent. (Level of Evidence: A)
(2) Pharmacological therapy is not recommended for main-
tenance of sinus rhythm in patients with advanced sinus
node disease or atrioventricular (AV) node dysfunction
unless they have a functioning electronic cardiac pace-
maker. (Level of Evidence: C)
5. Special considerations
a. Postoperative atrial ﬁbrillation
Class I
(1) Unless contraindicated, treatment with an oral beta
blocker to prevent postoperative AF is recommended
for patients undergoing cardiac surgery. (Level of
Evidence: A)
(2) Administration of AV nodal blocking agents is rec-
ommended to achieve rate control in patients who
develop postoperative AF. (Level of Evidence: B)
Class IIa
(1) Preoperative administration of amiodarone reduces the
incidence of AF in patients undergoing cardiac surgery
and represents appropriate prophylactic therapy for
patients at high risk for postoperative AF. (Level of
Evidence: A)
(2) It is reasonable to restore sinus rhythm by pharmacologi-
cal cardioversion with ibutilide or direct-current cardio-
version in patients who develop postoperative AF as
advised for nonsurgical patients. (Level of Evidence: B)
(3) It is reasonable to administer antiarrhythmic medi-
cations in an attempt to maintain sinus rhythm in
patients with recurrent or refractory postoperative AF,
as recommended for other patients who develop AF.
(Level of Evidence: B)
(4) It is reasonable to administer antithrombotic medication
in patients who develop postoperative AF, as
recommended for nonsurgical patients. (Level of
Evidence: B)
Class IIb
Prophylactic administration of sotalol may be considered
for patients at risk of developing AF following cardiac
surgery. (Level of Evidence: B)
b. Acute myocardial infarction
Class I
(1) Direct-current cardioversion is recommended for
patients with severe hemodynamic compromise or
intractable ischemia, or when adequate rate control
cannot be achieved with pharmacological agents in
patients with acute MI and AF. (Level of Evidence: C)
(2) Intravenous administration of amiodarone is rec-
ommended to slow a rapid ventricular response to AF
and improve LV function in patients with acute MI.
(Level of Evidence: C)
(3) Intravenous beta blockers and nondihydropyridine
calcium antagonists are recommended to slow a rapid
ventricular response to AF in patients with acute MI
who do not display clinical LV dysfunction, broncho-
spasm, or AV block. (Level of Evidence: C)
(4) For patients with AF and acute MI, administration of
unfractionated heparin by either continuous intravenous
infusion or intermittent subcutaneous injection is rec-
ommended in a dose sufﬁcient to prolong the activated
partial thromboplastin time to 1.5 to 2 times the control
value, unless contraindications to anticoagulation exist.
(Level of Evidence: C)
Class IIa
Intravenous administration of digitalis is reasonable to
slow a rapid ventricular response and improve LV function
in patients with acute MI and AF associated with severe LV
dysfunction and HF. (Level of Evidence: C)
Class III
The administration of class IC antiarrhythmic drugs is not
recommended in patients with AF in the setting of acute
MI. (Level of Evidence: C)
c. Management of atrial ﬁbrillation associated with the
Wolff-Parkinson-White (WPW) preexcitation syndrome
Class I
(1) Catheter ablation of the accessory pathway is rec-
ommended in symptomatic patients with AF who have
WPW syndrome, particularly those with syncope due to
rapid heart rate or those with a short bypass tract
refractory period. (Level of Evidence: B)
(2) Immediate direct-current cardioversion is recommended
to prevent ventricular ﬁbrillation in patients with a short
anterograde bypass tract refractory period in whom AF
occurs with a rapid ventricular response associated
with hemodynamic instability. (Level of Evidence: B)
(3) Intravenous procainamide or ibutilide is recommended
to restore sinus rhythm in patients with WPW in whom
AF occurs without hemodynamic instability in associ-
ation with a wide QRS complex on the electrocardiogram
(ECG) (greater than or equal to 120-ms duration) or with
a rapid preexcited ventricular response. (Level of
Evidence: C)
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Class IIa
Intravenous ﬂecainide or direct-current cardioversion is
reasonable when very rapid ventricular rates occur in
patients with AF involving conduction over an accessory
pathway. (Level of Evidence: B)
Class IIb
It may be reasonable to administer intravenous quinidine,
procainamide, disopyramide, ibutilide, or amiodarone to
hemodynamically stable patients with AF involving conduc-
tion over an accessory pathway. (Level of Evidence: B)
Class III
Intravenous administration of digitalis glycosides or non-
dihydropyridine calcium channel antagonists is not rec-
ommended in patients with WPW syndrome who have
preexcited ventricular activation during AF. (Level of
Evidence: B)
d. Hyperthyroidism
Class I
(1) Administration of a beta blocker is recommended to
control the rate of ventricular response in patients
with AF complicating thyrotoxicosis, unless contraindi-
cated. (Level of Evidence: B)
(2) In circumstances when a beta blocker cannot be used,
administration of a nondihydropyridine calcium
channel antagonist (diltiazem or verapamil) is rec-
ommended to control the ventricular rate in patients
with AF and thyrotoxicosis. (Level of Evidence: B)
(3) In patients with AF associated with thyrotoxicosis, oral
anticoagulation (INR 2.0 to 3.0) is recommended to
prevent thromboembolism, as recommended for AF
patients with other risk factors for stroke. (Level of
Evidence: C)
(4) Once a euthyroid state is restored, recommendations for
antithrombotic prophylaxis are the same as for patients
without hyperthyroidism. (Level of Evidence: C)
e. Management of atrial ﬁbrillation during pregnancy
Class I
(1) Digoxin, a beta blocker, or a nondihydropyridine calcium
channel antagonist is recommended to control the rate
of ventricular response in pregnant patients with AF.
(Level of Evidence: C)
(2) Direct-current cardioversion is recommended in preg-
nant patients who become hemodynamically unstable
due to AF. (Level of Evidence: C)
(3) Protection against thromboembolism is recommended
throughout pregnancy for all patients with AF (except
those with lone AF and/or low thromboembolic risk).
Therapy (anticoagulant or aspirin) should be chosen
according to the stage of pregnancy. (Level of
Evidence: C)
Class IIb
(1) Administration of heparin may be considered during the
ﬁrst trimester and last month of pregnancy for patients
with AF and risk factors for thromboembolism.
Unfractionated heparin may be administered either by
continuous intravenous infusion in a dose sufﬁcient to
prolong the activated partial thromboplastin time to
1.5 to 2 times the control value or by intermittent sub-
cutaneous injection in a dose of 10 000 to 20 000 units
every 12 h, adjusted to prolong the mid-interval (6 h
after injection) activated partial thromboplastin time
to 1.5 times control. (Level of Evidence: B)
(2) Despite the limited data available, subcutaneous admin-
istration of low-molecular-weight heparin may be con-
sidered during the ﬁrst trimester and last month of
pregnancy for patients with AF and risk factors for
thromboembolism. (Level of Evidence: C)
(3) Administration of an oral anticoagulant may be con-
sidered during the second trimester for pregnant
patients with AF at high thromboembolic risk. (Level
of Evidence: C)
(4) Administration of quinidine or procainamide may be
considered to achieve pharmacological cardioversion in
hemodynamically stable patients who develop AF
during pregnancy. (Level of Evidence: C)
f. Management of atrial ﬁbrillation in patients with
hypertrophic cardiomyopathy (HCM)
Class I
Oral anticoagulation (INR 2.0 to 3.0) is recommended in
patients with HCM who develop AF, as for other patients at
high risk of thromboembolism. (Level of Evidence: B)
Class IIa
Antiarrhythmic medications can be useful to prevent
recurrent AF in patients with HCM. Available data are insuf-
ﬁcient to recommend one agent over another in this situ-
ation, but (a) disopyramide combined with a beta blocker
or nondihydropyridine calcium channel antagonist or (b)
amiodarone alone is generally preferred. (Level of
Evidence: C)
g. Management of atrial ﬁbrillation in patients with
pulmonary disease
Class I
(1) Correction of hypoxemia and acidosis is the rec-
ommended primary therapeutic measure for patients
who develop AF during an acute pulmonary illness or
exacerbation of chronic pulmonary disease. (Level of
Evidence: C)
(2) A nondihydropyridine calcium channel antagonist (diltia-
zem or verapamil) is recommended to control the ven-
tricular rate in patients with obstructive pulmonary
disease who develop AF. (Level of Evidence: C)
(3) Direct-current cardioversion should be attempted in
patients with pulmonary disease who become hemody-
namically unstable as a consequence of AF. (Level of
Evidence: C)
Class III
(1) Theophylline and beta-adrenergic agonist agents are not
recommended in patients with bronchospastic lung
disease who develop AF. (Level of Evidence: C)
(2) Beta blockers, sotalol, propafenone, and adenosine are
not recommended in patients with obstructive lung
disease who develop AF. (Level of Evidence: C)
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II. Deﬁnition
A. Atrial ﬁbrillation
AF is a supraventricular tachyarrhythmia characterized by
uncoordinated atrial activation with consequent deterior-
ation of mechanical function. On the ECG, rapid oscillations,
or ﬁbrillatory waves that vary in amplitude, shape, and
timing, replace consistent P waves, and there is an irregular
ventricular response that is rapid when conduction is intact.1
The ventricular response depends on electrophysiological
properties of the AV node and other conducting tissues,
vagal and sympathetic tone, the presence or absence of
accessory pathways, and the action of drugs.2 When AV
block or ventricular or AV junctional tachycardia is present,
the cardiac cycles (R-R intervals) may be regular. In patients
with pacemakers, diagnosis of AF may require pacemaker
inhibition to expose ﬁbrillatory activity. An irregular, sus-
tained, wide-QRS-complex tachycardia suggests AF with
conduction over an accessory pathway or AF with bundle-
branch block. Atrial ﬂutter is usually readily distinguished
from AF. Extremely rapid rates (greater than 200 beats per
minute) suggest an accessory pathway or ventricular
tachycardia.
B. Related arrhythmias
AF may occur in association with atrial ﬂutter or atrial
tachycardia. The typical form of atrial ﬂutter is character-
ized by a saw-tooth pattern of regular atrial activation
called ﬂutter (f) waves on the ECG, particularly visible in
leads II, III, aVF, and V1. If untreated, the atrial rate typically
ranges from 240 to 320 beats per minute, with f waves
inverted in ECG leads II, III, and aVF and upright in lead
V1. The direction of activation in the right atrium (RA)
may be reversed, resulting in upright f waves in leads II,
III, and aVF and inversion in lead V1. Atrial ﬂutter may
degenerate into AF, and AF may convert to atrial ﬂutter.
Atrial ﬂutter is usually readily distinguished from AF, but
misdiagnosis may occur when ﬁbrillatory atrial activity is
prominent in more than 1 ECG lead.3
Focal atrial tachycardias, AV reentrant tachycardias, and
AV nodal reentrant tachycardias may also trigger AF. In
these tachycardias, distinct P waves are typically separated
by an isoelectric baseline, and their morphology may loca-
lize the origin of the arrhythmia.
III. Classiﬁcation
Various classiﬁcation systems have been proposed for AF
based on the ECG pattern,1 epicardial4 or endocavitary
recordings, mapping of atrial electrical activity, or clinical
features. Although the pattern of AF can change over
time, it may be helpful to characterize the arrhythmia at
a given moment. The classiﬁcation scheme recommended
here represents a consensus driven by a desire for simplicity
and clinical relevance.
The clinician should distinguish a ﬁrst-detected episode of
AF, whether or not symptomatic or self-limited, recognizing
the uncertainty about the actual duration of the episode and
about previous undetected episodes (Figure 1). After 2 or
more episodes, AF is considered recurrent. If the arrhythmia
terminates spontaneously, recurrent AF is designated parox-
ysmal; when sustained beyond 7 d, it is termed persistent.
Termination with pharmacological therapy or direct-current
cardioversion does not alter the designation. First-detected
AF may be either paroxysmal or persistent. The category
of persistent AF also includes cases of long-standing AF
(e.g., longer than 1 y), usually leading to permanent AF, in
which cardioversion has failed or has been foregone.
These categories are not mutually exclusive, and a par-
ticular patient may have several episodes of paroxysmal
AF and occasional persistent AF, or the reverse, but it is
practical to categorize a given patient by his or her most fre-
quent presentation. The deﬁnition of permanent AF is often
arbitrary, and the duration refers both to individual episodes
and to how long the diagnosis has been present in a given
patient. Thus, in a patient with paroxysmal AF, episodes
lasting seconds to hours may occur repeatedly for years.
This terminology applies to episodes lasting longer than
30 s without a reversible cause. Secondary AF in the
setting of acute MI, cardiac surgery, pericarditis, myocar-
ditis, hyperthyroidism, or acute pulmonary disease is con-
sidered separately. In these situations, AF is not the
primary problem, and concurrent treatment of the under-
lying disorder usually terminates the arrhythmia.
Conversely, when AF occurs in the course of a concurrent
disorder like well-controlled hypothyroidism, the general
principles for management of the arrhythmia apply.
The term lone AF applies to individuals younger than 60 y
without clinical or echocardiographic evidence of cardiopul-
monary disease, including hypertension.5 These patients
have a favorable prognosis with respect to thromboembo-
lism and mortality. Over time, patients move out of the
lone AF category due to aging or development of cardiac
abnormalities such as enlargement of the LA, and the risks
of thromboembolism and mortality rise. The term nonvalvu-
lar AF refers to cases without rheumatic mitral valve
disease, prosthetic heart valve, or valve repair.
IV. Epidemiology and prognosis
AF is the most common arrhythmia in clinical practice,
accounting for approximately one third of hospitalizations
for cardiac rhythm disturbances. An estimated 2.3 million
people in North America and 4.5 million people in the
Figure 1 Patterns of atrial ﬁbrillation (AF). 1, Episodes that generally last 7
d or less (most less than 24 h); 2, episodes that usually last more than 7 d; 3,
cardioversion failed or not attempted; and 4, both paroxysmal and persistent
AF may be recurrent.
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European Union have paroxysmal or persistent AF.9 During
the past 20 y, hospital admissions for AF have increased by
66%7 due to the aging of the population, a rising prevalence
of chronic heart disease, more frequent diagnosis through
use of ambulatory monitoring devices, and other factors.
AF is an extremely expensive public health problem
(approximately E3000 [approximately U.S. $3600] annually
per patient)8; the total cost burden approaches E13.5
billion (approximately U.S. $15.7 billion) in the European
Union.
A. Prevalence
The estimated prevalence of AF is 0.4% to 1% in the general
population,9 increasing with age to 8% in those older than
80 y.10 Among men, the age-adjusted prevalence has more
than doubled over a generation,10 while the prevalence in
women has remained constant.11 The median age of patients
with AF is about 75 y. The number of men and women with
AF is about equal, but approximately 60% of those over
75 y old are female. Based on limited data, the age-adjusted
risk of developing AF in blacks seems less than half that in
whites.
In population-based studies, patients with no history of
cardiopulmonary disease account for fewer than 12% of all
cases of AF.10 In case series, however, the observed pro-
portion of lone AF was sometimes greater than 30%.12
B. Incidence
In prospective studies, the incidence of AF increases from
less than 0.1% per year in people younger than 40 y to
over 1.5% per year among women and 2% among men older
than 80 y.13 In patients treated for HF, the 3-y incidence of
AF was almost 10%.14 Angiotensin inhibition may be associ-
ated with a reduced incidence of AF in patients with HF15
and hypertension.16
C. Prognosis
AF is associated with an increased long-term risk of stroke,17
HF, and all-cause mortality, especially among women.18 The
mortality rate of patients with AF is about double that of
patients in normal sinus rhythm and is linked to the severity
of underlying heart disease.19 In the Etude en Activite´
Libe´rale sur la Fibrillation Auriculaire Study (ALFA), about
two thirds of the 5% annualized mortality was attributed
to cardiovascular causes.12 In large HF trials (COMET
[Carvedilol Or Metoprolol European Trial], Val-HeFT
[Valsartan Heart Failure Trial]), AF was a strong indepen-
dent risk factor for mortality and morbidity.20,21 HF
promotes AF, AF aggravates HF, and individuals with either
condition who develop the alternate condition share a
poor prognosis.22 Thus, managing patients with the
associated conditions is a major challenge, and randomized
trials are needed to investigate the impact of AF on
prognosis in HF.
The rate of ischemic stroke among patients with nonvalv-
ular AF averages 5% per year, 2 to 7 times that of people
without AF.23 One of every 6 strokes occurs in a patient
with AF, and when TIAs and clinically ‘silent’ strokes
detected by brain imaging are considered, the rate of
brain ischemia accompanying nonvalvular AF exceeds 7%
per year.24 In patients with rheumatic heart disease and
AF in the Framingham Heart Study, stroke risk was
increased 17-fold compared with age-matched controls,25
and attributable risk was 5 times greater than in those
with nonrheumatic AF.23 The risk of stroke increased with
age; the annual risk of stroke attributable to AF was 1.5%
in participants aged 50 to 59 y and 23.5% in those aged
80 to 89 y.23
V. Pathophysiological mechanisms
A. Atrial factors
1. Atrial pathology as a cause of atrial ﬁbrillation
The most frequent histopathological changes in AF are atrial
ﬁbrosis and loss of atrial muscle mass, but it is difﬁcult to
distinguish changes due to AF from those due to associated
heart disease. Atrial ﬁbrosis may precede the onset of
AF,26 and juxtaposition of patchy ﬁbrosis with normal atrial
ﬁbers may account for nonhomogeneity of conduction.27
Interstitial ﬁbrosis may result from apoptosis leading to
replacement of atrial myocytes,28 loss of myoﬁbrils,
accumulation of glycogen granules, disruption of cell coup-
ling at gap junctions,29 and organelle aggregates30 and
may be triggered by atrial dilation in any type of heart
disease associated with AF.
Patients with valvular heart disease who have mild ﬁbrosis
respond more successfully to cardioversion than those with
severe ﬁbrosis, and ﬁbrosis is thought to contribute to
persistent AF.31 The concentration of membrane-bound
glycoproteins that regulate cell–cell and cell–matrix inter-
actions (disintegrin and metalloproteinases) in human
atrial myocardium has been reported to double during AF,
and these changes may contribute to atrial dilation in
patients with longstanding AF. Dilation of the atria acti-
vates several molecular pathways, including the renin-
angiotensin-aldosterone system (RAAS). Angiotensin II is
upregulated in response to stretch,32 and atrial tissue from
patients with persistent AF demonstrates increased
expression of angiotensin-converting enzyme (ACE).33
Angiotensin inhibition may prevent AF by reducing ﬁbrosis.34
Atrial dilation and interstitial ﬁbrosis in HF facilitate
sustained AF.35 The regional electrical silence (suggesting
scar), voltage reduction, and conduction slowing described
in patients with HF are similar to changes in the atria that
occur as a consequence of aging.36
2. Mechanisms of atrial ﬁbrillation
Available data support a ‘focal’ triggering mechanism invol-
ving automaticity or multiple reentrant wavelets, but these
mechanisms are not mutually exclusive and may coexist
(Figure 2).
The important observation that a focal source for AF could
be identiﬁed and ablation of this source could extinguish AF37
supported a focal origin. While pulmonary veins (PVs) are the
most frequent source of these rapidly atrial impulses, foci
have also been found in the superior vena cava, ligament
of Marshall, left posterior free wall, crista terminalis, and
coronary sinus.37–40 In histological studies, cardiac muscle
with preserved electrical properties extends into the PVs,41
and the primacy of PVs as triggers of AF has prompted sub-
stantial research into the anatomical and electrophysiologi-
cal properties of these structures. Atrial tissue in the PVs
of patients with AF has shorter refractory periods than in
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control patients or other parts of the atria in patients with
AF.42,43 This heterogeneity of conduction may promote
reentry and form a substrate for sustained AF.44
The multiple-wavelet hypothesis as the mechanism of
reentrant AF46 involves fractionation of wave fronts propa-
gating through the atria and self-perpetuating ‘daughter
wavelets.’ In this model, the number of wavelets at any
time depends on the refractory period, mass, and conduc-
tion velocity in different parts of the atria. A large atrial
mass with a short refractory period and delayed conduction
increases the number of wavelets, favoring sustained AF.
Simultaneous recordings from multiple electrodes supported
the multiple-wavelet hypothesis in human subjects.47
Although the multiple-wavelet hypothesis was for years
the dominant theory explaining the mechanism of AF, data
from experimental47a and clinical47b,47c mapping studies
challenge this notion. In patients with idiopathic paroxysmal
AF, widespread distribution of abnormal electrograms in the
RA predicts development of persistent AF,48 suggesting the
importance of an abnormal substrate in the maintenance
of AF. Furthermore, in patients with persistent AF under-
going conversion to sinus rhythm, intra-atrial conduction is
prolonged compared with a control group, especially
among those who develop recurrent AF.49 Among patients
with HF, prolongation of the P wave on signal-averaged
ECG analysis was more frequent in those prone to paroxys-
mal AF.50 Because many of these observations were made
prior to onset of clinical AF, the ﬁndings cannot be ascribed
to atrial remodeling that occurs as a consequence of AF, and
the degree to which changes in the atrial architecture con-
tribute to the initiation and maintenance of AF is not known.
3. Atrial electrical remodeling
Pharmacological or direct-current cardioversion of AF has a
higher success rate when AF has been present for less than
24 h,51 whereas more prolonged AF makes restoring and
maintaining sinus rhythm less likely. These observations
gave rise to the adage ‘atrial ﬁbrillation begets atrial ﬁbril-
lation.’ The notion that AF is self-perpetuating takes exper-
imental support from a goat model using an automatic atrial
ﬁbrillator that detected spontaneous termination of AF and
reinduced the arrhythmia by electrical stimulation.52
Initially, electrically induced AF terminated spontaneously.
After repeated inductions, however, the episodes became
progressively more sustained until AF persisted at a more
rapid atrial rate.52 The increasing propensity to AF was
related to progressive shortening of effective refractory
periods with increasing episode duration, a phenomenon
known as electrophysiological remodeling.
In addition to remodeling and changes in electrical refrac-
toriness, prolonged AF disturbs atrial contractile function.
After a period of persistent AF, recovery of atrial contraction
can be delayed for days or weeks following the restoration
of sinus rhythm, and this has important implications for
the duration of anticoagulation after cardioversion. (See
Section VIII.B.2, Preventing thromboembolism.)
4. Other factors contributing to atrial ﬁbrillation
Data are accumulating on the importance of the RAAS in the
genesis of AF.53 Irbesartan plus amiodarone was associated
with a lower incidence of recurrent AF after cardioversion
than amiodarone alone,15 and treatment with angiotensin
inhibitors and diuretics reduced the incidence of AF after
catheter ablation of atrial ﬂutter.54 Inhibition of the RAAS,
alone or in combination with other therapies, may prevent
the onset or maintenance of AF through several mechan-
isms,55 including lower atrial pressure and wall stress, pre-
vention of structural remodeling (ﬁbrosis, dilation, and
hypertrophy) in both the LA and left ventricle (LV), inhi-
bition of neurohumoral activation, reducing blood pressure,
prevention or amelioration of HF, and avoidance of hypoka-
lemia. Treatment with trandolapril reduced the incidence of
AF in patients with LV dysfunction following acute MI,56 but
it remains to be clariﬁed whether this effect is related to
reversal of structural or electrical remodeling in the atria
or to another mechanism.
Other factors potentially involved in the induction or
maintenance of AF are outlined in Table 2. Among these is
inﬂammation, and ongoing studies are exploring the use of
statin-type lipid-lowering drugs with this mechanism in
mind.
B. Atrioventricular conduction
1. General aspects
In the absence of an accessory pathway or His-Purkinje dys-
function, the AV node limits conduction during AF.57 Of the
multiple atrial inputs to the AV node that have been ident-
iﬁed, 2 seem dominant: one directed posteriorly via the
crista terminalis and the other aimed anteriorly via the
interatrial septum. Other factors affecting AV conduction
are the intrinsic refractoriness of the AV node, concealed
conduction, and autonomic tone. Concealed conduction
plays a prominent role in determining the ventricular
response during AF58 by altering the refractoriness of the
AV node and slowing or blocking atrial impulses and may
explain the irregularity of ventricular response during AF.59
When the atrial rate is relatively slow during AF, the ventri-
cular rate tends to rise and, conversely, higher atrial rate is
associated with slower ventricular rate.
Increased parasympathetic and reduced sympathetic tone
exert negative dromotropic effects on AV nodal conduction,
while the opposite is true in states of decreased parasympa-
thetic and increased sympathetic tone.58 Vagal tone also
Figure 2 Posterior view of principal electrophysiological mechanisms of
atrial ﬁbrillation. (A) Focal activation. The initiating focus (indicated by
the star) often lies within the region of the pulmonary veins. The resulting
wavelets represent ﬁbrillatory conduction, as in multiple-wavelet reentry.
(B) Multiple-wavelet reentry. Wavelets (indicated by arrows) randomly
re-enter tissue previously activated by the same or another wavelet. The
routes the wavelets travel vary. Reproduced with permission from Konings
KT, Kirchhof CJ, Smeets JR, et al. High-density mapping of electrically
induced atrial ﬁbrillation in humans. Circulation 1994;89:1665–1680.45 LA
indicates left atrium; PV, pulmonary vein; ICV, inferior vena cava; SCV,
superior vena cava; and RA, right atrium.
ACC/AHA/ESC Guidelines 1991
Downloaded from https://academic.oup.com/eurheartj/article-abstract/27/16/1979/408863
by guest
on 02 April 2018
enhances the negative chronotropic effects of concealed
conduction in the AV node.60 Fluctuations in autonomic
tone can produce disparate ventricular responses to AF,
exempliﬁed by a slow ventricular rate during sleep but
accelerated ventricular response during exercise. Digitalis,
which slows the ventricular rate during AF predominantly
by increasing vagal tone, is more effective for controlling
heart rate at rest in AF but less effective during activity.
2. Atrioventricular conduction in preexcitation
syndromes
Conduction across an accessory pathway during AF can result
in dangerously rapid ventricular rates.2 Transition of AV
reentry into AF in patients with the WPW syndrome can
produce a rapid ventricular response that degenerates into
lethal ventricular ﬁbrillation.61 Drugs that lengthen refrac-
toriness and slow conduction across the AV node (such as
digitalis, verapamil, or diltiazem) do not block conduction
over the accessory pathway and may accelerate the ventri-
cular rate. Hence, these agents are contraindicated in this
situation.62 Although the potential for beta blockers to
potentiate conduction across the accessory pathway is con-
troversial, caution should be exercised in the use of these
agents as well in patients with AF associated with
preexcitation.
C. Myocardial and hemodynamic consequences of
atrial ﬁbrillation
Among factors that affect hemodynamic function during AF
are loss of synchronous atrial mechanical activity, irregular
ventricular response, rapid heart rate, and impaired
coronary arterial blood ﬂow. Loss of atrial contraction may
markedly decrease cardiac output, especially when diastolic
ventricular ﬁlling is impaired by mitral stenosis, hyper-
tension, HCM, or restrictive cardiomyopathy. Myocardial
contractility is not constant during AF because of
force–interval relationships associated with variations in
cycle length.63 In patients with persistent AF, mean LA and
RA volumes increase over time64 and restoration and main-
tenance of sinus rhythm decrease these volumes.65
Moreover, TEE has demonstrated that contractile function
and blood ﬂow velocity in the LAA recover after cardiover-
sion, consistent with a reversible atrial cardiomyopathy in
patients with AF.66 Although one might expect restoration
of sinus rhythm to improve the other hemodynamic charac-
teristics associated with AF, this is not always the case.67
Beyond its effects on atrial function, a persistently elev-
ated ventricular rate during AF may adversely increase
mitral regurgitation and produce dilated ventricular cardio-
myopathy (tachycardia-induced cardiomyopathy).2,68 It is
important to recognize this cause of cardiomyopathy, in
which HF is a consequence rather than the cause of AF,
because control of the ventricular rate may lead to reversal
of the myopathic process. A variety of hypotheses have been
proposed to explain tachycardia-mediated cardiomyopathy
on the basis of myocardial energy depletion, ischemia,
abnormal calcium regulation, and remodeling, but the
actual mechanisms are still unclear.69
D. Thromboembolism
Although ischemic stroke and systemic arterial occlusion in
AF are generally attributed to embolism of thrombus from
the LA, the pathogenesis of thromboembolism is
complex.70 Up to 25% of strokes in patients with AF may
be due to intrinsic cerebrovascular diseases, other cardiac
sources of embolism, or atheromatous pathology in the
proximal aorta.71,72 The annual risk of stroke in patients
with AF is in the range of 3% to 8% per year, depending on
associated stroke risk factors.23 About half of all elderly
AF patients have hypertension (a major risk factor for cer-
ebrovascular disease), and approximately 12% have carotid
artery stenosis.73 Carotid atherosclerosis is not substantially
more prevalent in AF patients with stroke than in patients
without AF, however, and is probably a relatively minor con-
tributing epidemiological factor.74
1. Pathophysiology of thrombus formation
Thrombus formation as a result of stasis in the LAA is thought
to represent the main source of disabling cardioembolic
ischemic strokes in patients with AF. These thrombi cannot
be regularly examined by precordial (transthoracic) echo-
cardiography,75 and TEE is a more sensitive and speciﬁc
method to assess LAA function76 and detect thrombus
formation. Serial TEE studies of the LA77 and LAA78 during
conversion of AF to sinus rhythm demonstrated reduced
Table 2 Etiologies and factors predisposing patients to AF
Electrophysiological abnormalities
Enhanced automaticity (focal AF)
Conduction abnormality (reentry)
Atrial pressure elevation
Mitral or tricuspid valve disease
Myocardial disease (primary or secondary, leading to systolic or
diastolic dysfunction)
Semilunar valvular abnormalities (causing ventricular
hypertrophy)
Systemic or pulmonary hypertension (pulmonary embolism)
Intracardiac tumors or thrombi
Atrial ischemia
Coronary artery disease
Inﬂammatory or inﬁltrative atrial disease
Pericarditis
Amyloidosis
Myocarditis
Age-induced atrial ﬁbrotic changes
Drugs
Alcohol
Caffeine
Endocrine disorders
Hyperthyroidism
Pheochromocytoma
Changes in autonomic tone
Increased parasympathetic activity
Increased sympathetic activity
Primary or metastatic disease in or adjacent to the atrial wall
Postoperative
Cardiac, pulmonary, or esophageal
Congenital heart disease
Neurogenic
Subarachnoid hemorrhage
Nonhemorrhagic, major stroke
Idiopathic (lone AF)
Familial AF
AF indicates atrial ﬁbrillation.
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LAA ﬂow velocities related to loss of organized mechanical
contraction during AF. Thrombi are more often encountered
in AF patients with ischemic stroke than in those without
stroke.79 Although clinical management is based on the pre-
sumption that thrombus formation requires continuation of
AF for approximately 48 h, thrombi have been identiﬁed
by TEE within shorter intervals.80,81
After successful cardioversion, regardless of whether the
method is electrical, pharmacological, or spontaneous,82
stunning of the LAA may account for an increased risk of
thromboembolic events. Atrial stunning is at a maximum
immediately after cardioversion; progressive improvement
of atrial transport function usually occurs within a few
days but sometimes takes as long as 3 to 4 wk, depending
on the duration of AF.82,83 This corroborates the clinical
observation that following cardioversion, more than 80% of
thromboembolic events occur during the ﬁrst 3 d and
almost all occur within 10 d.84 TEE studies have veriﬁed res-
olution of thrombus in the majority of patients.85 Similar
observations have deﬁned the dynamic nature of LA/LAA
dysfunction following conversion of AF, providing a mechan-
istic rationale for anticoagulation for several weeks before
and after successful cardioversion. Although stunning may
be milder with certain associated conditions or a short dur-
ation of AF, anticoagulation is recommended during cardio-
version and for at least 4 wk afterward in all patients with
AF lasting longer than 48 h or of unknown duration, including
lone AF, except when contraindicated.
Decreased ﬂow within the LA/LAA during AF has been
associated with spontaneous echo contrast (SEC), thrombus
formation, and embolic events.86,87 Speciﬁcally, SEC, or
‘smoke,’ a swirling haze of variable density, may be
detected by transthoracic echocardiography or TEE
imaging under low-ﬂow conditions.88 There is evidence
that SEC is a marker of stasis caused by AF,89,90 but the
utility of SEC for prospective thromboembolic risk stratiﬁca-
tion beyond that achieved by clinical assessment alone has
not been conﬁrmed.
LAA ﬂow velocities are lower in patients with atrial ﬂutter
than is usually seen during sinus rhythm but higher than in
AF. Whether this accounts for any lower prevalence of LAA
thrombus or thromboembolism associated with atrial
ﬂutter is uncertain. As in AF, atrial ﬂutter is associated
with low appendage emptying velocities following cardio-
version with the potential for thromboembolism91 and anti-
coagulation is recommended similarly. (See Section 8.1.4.1.3
in the full-text guidelines, Therapeutic implications.)
2. Clinical implications
Complex thromboembolic mechanisms are operative in AF
and involve the interplay of risk factors related to atrial
stasis, endothelial dysfunction, and systemic and possibly
local hypercoagulability. The strong association between
hypertension and stroke in AF is probably mediated primarily
by embolism originating in the LAA,72 but hypertension also
increases the risk of noncardioembolic strokes in patients
with AF.92 Whether control of hypertension lowers the risk
for cardioembolic stroke in patients with AF is a vital
question.
The increasing stroke risk in patients with AF with advan-
cing age is also multifactorial. Aging is a risk factor for
atherosclerosis, and plaques in the aortic arch are associ-
ated with stroke independent of AF.93 Age is a more potent
risk factor when combined with other risk factors such as
hypertension or female gender, and women over age 75 y
with AF are at particular risk for stroke.94
LV systolic dysfunction, as indicated by a history of HF or
echocardiographic assessment, predicts ischemic stroke in
patients with AF who receive no antithrombotic therapy95
but not in moderate-risk patients given aspirin.96,97 LV systo-
lic dysfunction has been associated both with LA thrombus
and with noncardioembolic strokes in patients with AF.72,98
VI. Causes, associated conditions, clinical
manifestations, and quality of life
A. Causes and associated conditions
1. Reversible causes of atrial ﬁbrillation
AF may be related to acute temporary causes, including
alcohol intake (‘holiday heart syndrome’), surgery, electro-
cution, MI, pericarditis, myocarditis, pulmonary embolism or
other pulmonary diseases, hyperthyroidism, and other meta-
bolic disorders. In such cases, successful treatment of the
underlying condition often eliminates AF. In the setting of
acute MI, the development of AF portends an adverse prog-
nosis compared with preinfarct AF or sinus rhythm.99,100
When AF is associated with atrial ﬂutter, WPW syndrome,
or AV nodal reentrant tachycardia, treatment of the
primary arrhythmia reduces or eliminates the incidence of
recurrent AF.101 AF is a common early postoperative compli-
cation of cardiac and thoracic surgery.
2. Atrial ﬁbrillation without associated heart disease
Approximately 30% to 45% of cases of paroxysmal AF and 20%
to 25% of cases of persistent AF occur in young patients
without demonstrable underlying disease (‘lone AF’).12 AF
can present as an isolated or familial arrhythmia, although
a causal underlying disease may appear over time.102
Although AF may occur in the elderly without underlying
heart disease, the changes in cardiac structure and function
that accompany aging, such as increased myocardial stiff-
ness, may be associated with AF, just as heart disease in
older patients may be coincidental and unrelated to AF.
3. Medical conditions associated with atrial ﬁbrillation
Obesity is an important risk factor for the development of
AF.103 After adjustment for clinical risk factors, the excess
risk of AF appears related to LA dilation. There is a graded
increase in LA size as body mass index increases from
normal to the overweight and obese categories, and
weight has been linked to regression of LA enlargement.104
These ﬁndings suggest a physiological link between
obesity, AF, and stroke and raise the intriguing possibility
that weight reduction may decrease the risk associated
with AF.
4. Atrial ﬁbrillation with associated heart disease
Speciﬁc cardiovascular conditions associated with AF include
valvular heart disease (most often mitral valve disease), HF,
coronary artery disease (CAD), and hypertension, particu-
larly when LV hypertrophy (LVH) is present. In addition, AF
may be associated with HCM, dilated cardiomyopathy, or
congenital heart disease, especially atrial septal defect in
adults. Potential etiologies also include restrictive cardio-
myopathies (e.g., amyloidosis, hemochromatosis, and
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endomyocardial ﬁbrosis), cardiac tumors, and constrictive
pericarditis. Other heart diseases, such as mitral valve pro-
lapse with or without mitral regurgitation, calciﬁcation of
the mitral annulus, cor pulmonale, and idiopathic dilation
of the RA, have been associated with a high incidence of
AF. AF is commonly encountered in patients with sleep
apnea syndrome, but whether the arrhythmia is provoked
by hypoxia, another biochemical abnormality, changes in
pulmonary dynamics or RA factors, changes in autonomic
tone, or systemic hypertension has not been determined.
5. Familial atrial ﬁbrillation
Familial AF, deﬁned as lone AF running in a family, is more
common than previously recognized but should be distin-
guished from AF secondary to other genetic diseases like
familial cardiomyopathies. The likelihood of developing AF
is increased among the offspring of parents with AF,
suggesting a familial susceptibility to the arrhythmia, but
the mechanisms associated with transmission are not
necessarily electrical, because the relationship has also
been seen in patients with a family history of hypertension,
diabetes, or HF.105 The molecular defects responsible for
familial AF are largely unknown. Speciﬁc chromosomal loci
linked to AF in some families106 suggest distinct genetic
mutations.107
6. Autonomic inﬂuences in atrial ﬁbrillation
Autonomic inﬂuences play an important role in the initiation
of AF. Measurement of heart rate variability (HRV) reﬂects
changes in relative autonomic modulation rather than the
absolute level of sympathetic or parasympathetic tone. It
appears, however, that the balance between sympathetic
and vagal inﬂuences is important as a predictor of AF.
Vagal predominance has been observed in the minutes pre-
ceding the onset of AF in some patients with structurally
normal hearts, while in others there is a shift toward sym-
pathetic predominance.108,109 Although certain patients
can be characterized in terms of a vagal or an adrenergic
form of AF, these cases likely represent the extremes of
either inﬂuence.110 In general, vagally mediated AF occurs
at night or after meals, while adrenergically induced AF
typically occurs during the daytime.111 In patients with
vagally mediated AF, the more common form, adrenergic
blocking drugs or digitalis sometimes worsen symptoms.
For AF of the adrenergic type, beta blockers are the initial
treatment of choice.
B. Clinical manifestations
AF may cause a sensation of palpitations, have distinct
hemodynamic or thromboembolic consequences, or follow
an asymptomatic period of unknown duration. Ambulatory
ECG recordings and device-based monitoring reveal that
individuals may experience periods of both symptomatic
and asymptomatic AF.112–114 Over time, palpitation may dis-
appear, such that patients in whom the arrhythmia has
become permanent may become asymptomatic. This is
particularly common among the elderly. Some patients
experience symptoms only during paroxysmal AF, or only
intermittently during sustained AF. When present, symptoms
of AF vary with the irregularity and rate of ventricular
response, underlying functional status, duration of AF, and
individual patient factors.115
The initial presentation of AF may be an embolic compli-
cation or exacerbation of HF, but most patients complain of
palpitations, chest pain, dyspnea, fatigue, lightheadedness,
or syncope. Polyuria may be associated with the release of
atrial natriuretic peptide, particularly as episodes of AF
begin or terminate. AF associated with a sustained, rapid
ventricular response can lead to tachycardia-mediated car-
diomyopathy, especially in patients unaware of the arrhyth-
mia. Syncope is an uncommon complication that can occur
upon conversion in patients with sinus node dysfunction or
because of rapid ventricular rates in patients with HCM,
valvular aortic stenosis, or an accessory pathway.
C. Quality of life
Available data suggest that quality of life is considerably
impaired in patients with AF compared to age-matched con-
trols. Sustained sinus rhythm is associated with improved
quality of life and better exercise performance than AF in
some studies but not others.116 In a typical study, a majority
of patients with paroxysmal AF considered the arrhythmia
disruptive of lifestyle, but this perception was not associ-
ated with either the frequency or duration of symptomatic
episodes.117
VII. Clinical evaluation
A. Basic evaluation of the patient with atrial
ﬁbrillation
1. Clinical history and physical examination
The diagnosis of AF requires conﬁrmation by ECG recording,
sometimes in the form of bedside telemetry or ambulatory
Holter recordings. The initial evaluation of a patient with
suspected or proven AF involves characterizing the pattern
of the arrhythmia as paroxysmal or persistent, determining
its cause, and deﬁning associated cardiac and extracardiac
factors pertinent to the etiology, tolerability, and manage-
ment. The work-up and therapy can usually be accomplished
in a single outpatient encounter (Table 3), unless the rhythm
has not been speciﬁcally documented and additional moni-
toring is necessary.
Physical examination may suggest AF on the basis of irre-
gular pulse, irregular jugular venous pulsations, variation in
the intensity of the ﬁrst heart sound, or absence of a fourth
sound heard previously during sinus rhythm. The ﬁndings are
similar in patients with atrial ﬂutter, except that the rhythm
may be regular and rapid venous oscillations may occasion-
ally be visible in the jugular pulse.
2. Investigations
The diagnosis of AF requires ECG documentation by at least
a single-lead recording during the arrhythmia. In patients
with implanted pacemakers or deﬁbrillators, the diagnostic
and memory functions may allow accurate and automatic
detection.118 A chest radiograph is valuable mostly to
detect intrinsic pulmonary pathology and evaluate the
pulmonary vasculature. It is important that thyroid, renal,
and hepatic functions, serum electrolytes, and the hemo-
gram be measured at least once in the course of evalu-
ation.119 All patients with AF should also have
2-dimensional, Doppler echocardiography to assess LA and
LV dimensions, LV wall thickness, and function and to
exclude occult valvular or pericardial disease and HCM.
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Thrombus in the LA or LAA is seldom detected without TEE.
Among the TEE features associated with thromboembolism
in patients with nonvalvular AF are thrombus, SEC,
reduced LAA ﬂow velocity, and aortic atheromatous abnorm-
alities,120 but prospective investigations are needed to
compare these TEE ﬁndings with clinical and transthoracic
echocardiographic predictors of thromboembolism.
Detection of LA/LAA thrombus in the setting of stroke or sys-
temic embolism is convincing evidence of a cardiogenic
mechanism.81
VIII. Management
A. Strategic objectives
Management of patients with AF involves 3 objectives—rate
control, prevention of thromboembolism, and correction
of the rhythm disturbance—and these are not mutually
exclusive. The initial management decision involves primar-
ily a rate control or rhythm control strategy. Under the rate
control strategy, the ventricular rate is controlled with no
commitment to restore or maintain sinus rhythm. The
rhythm control strategy attempts restoration and/or main-
tenance of sinus rhythm. The latter strategy also requires
attention to rate control. Depending on the patient’s
course, the strategy initially chosen may prove unsuccessful
and the alternate strategy is then adopted. Regardless of
whether the rate control or rhythm control strategy is
pursued, attention must also be directed to antithrombotic
therapy for prevention of thromboembolism.
B. Pharmacological and nonpharmacological
treatment options
Drugs and ablation are effective for both rate and rhythm
control, and in special circumstances surgery may be the
preferred option. Regardless of the approach, the need for
anticoagulation is based on stroke risk and not on whether
sinus rhythm is maintained. For rhythm control, drugs are
typically the ﬁrst choice and LA ablation is a second-line
choice, especially in patients with symptomatic lone AF.
In some patients, especially young persons with very symp-
tomatic AF who need sinus rhythm, radiofrequency ablation
may be preferred over years of drug therapy. Patients with
preoperative AF undergoing cardiac surgery face a unique
opportunity. While few are candidates for a stand-alone sur-
gical procedure to cure AF using the maze or LA ablation
techniques, these approaches can be an effective adjunct
to coronary bypass or valve repair surgery to prevent recur-
rent postoperative AF. Because the LAA is the site of greater
than 95% of detected thrombi, this structure is commonly
removed from the circulation during cardiac surgery in
patients at risk of developing postoperative AF, although
this has not been proved to prevent stroke.121
1. Heart rate control versus rhythm control
For patients with symptomatic AF lasting many weeks, initial
therapy may be anticoagulation and rate control while the
long-term goal is to restore sinus rhythm. When cardiover-
sion is contemplated and the duration of AF is unknown or
exceeds 48 h, patients who do not require long-term anti-
coagulation may beneﬁt from short-term anticoagulation.
If rate control offers inadequate symptomatic relief, restor-
ation of sinus rhythm becomes a clear long-term goal. Early
Table 3 Clinical evaluation in patients with AF
Minimum evaluation
1. History and physical examination, to deﬁne
Presence and nature of symptoms associated with AF
Clinical type of AF (ﬁrst episode, paroxysmal, persistent, or
permanent)
Onset of the ﬁrst symptomatic attack or date of discovery of AF
Frequency, duration, precipitating factors, and modes of
termination of AF
Response to any pharmacological agents that have been
administered
Presence of any underlying heart disease or other reversible
conditions (e.g., hyperthyroidism or alcohol consumption)
2. Electrocardiogram, to identify
Rhythm (verify AF)
LV hypertrophy
P-wave duration and morphology or ﬁbrillatory waves
Preexcitation
Bundle-branch block
Prior MI
Other atrial arrhythmias
To measure and follow the R-R, QRS, and QT intervals in
conjunction with antiarrhythmic drug therapy
3. Transthoracic echocardiogram, to identify
Valvular heart disease
LA and RA size
LV size and function
Peak RV pressure (pulmonary hypertension)
LV hypertrophy
LA thrombus (low sensitivity)
Pericardial disease
4. Blood tests of thyroid, renal, and hepatic function
For a ﬁrst episode of AF, when the ventricular rate is difﬁcult to
control
Additional testing
One or several tests may be necessary.
1. Six-minute walk test
If the adequacy of rate control is in question
2. Exercise testing
If the adequacy of rate control is in question (permanent AF)
To reproduce exercise-induced AF
To exclude ischemia before treatment of selected patients
with a type IC antiarrhythmic drug
3. Holter monitoring or event recording
If diagnosis of the type of arrhythmia is in question
As a means of evaluating rate control
4. Transesophageal echocardiography
To identify LA thrombus (in the LA appendage)
To guide cardioversion
5. Electrophysiological study
To clarify the mechanism of wide-QRS-complex tachycardia
To identify a predisposing arrhythmia such as atrial ﬂutter or
paroxysmal supraventricular tachycardia
To seek sites for curative ablation or AV conduction block/
modiﬁcation
6. Chest radiograph, to evaluate
Lung parenchyma, when clinical ﬁndings suggest an
abnormality
Pulmonary vasculature, when clinical ﬁndings suggest an
abnormality
Type IC refers to the Vaughan Williams classiﬁcation of antiarrhythmic
drugs (see Table 14).
AF indicates atrial ﬁbrillation; AV, atrioventricular; LA, left atrial; LV,
left ventricular; MI, myocardial infarction; RA, right atrial; and RV, right
ventricular.
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cardioversion may be necessary if AF causes hypotension or
worsening HF. In contrast, amelioration of symptoms by rate
control in older patients may steer the clinician away from
attempts to restore sinus rhythm. In some circumstances,
when the initiating pathophysiology of AF is reversible, as
for instance in the setting of thyrotoxicosis or after
cardiac surgery, no long-term therapy may be necessary.
Randomized trials comparing outcomes of rhythm versus
rate control strategies in patients with AF are summarized
in Tables 4–6. Among these, AFFIRM (Atrial Fibrillation
Follow-up Investigation of Rhythm Management) found no
difference in mortality or stroke rate between patients
assigned to one strategy or the other. The RACE (Rate
Control vs. Electrical cardioversion for persistent atrial
ﬁbrillation) trial found rate control not inferior to rhythm
control for prevention of death and morbidity. Clinically
silent recurrences of AF in asymptomatic patients treated
with antiarrhythmic drugs may be responsible for throm-
boembolic events after withdrawal of anticoagulation.
Hence, patients at high risk for stroke may require anticoa-
gulation regardless of whether the rate control or rhythm
control strategy is chosen, but the AFFIRM trial was not
designed to address this question.122 While secondary ana-
lyses support this notion, the stroke rate in patients assigned
to rhythm control who stopped warfarin is uncertain, and
additional research is needed to address this important
question.
Information about the effects of antiarrhythmic and
chronotropic therapies on quality of life is inconsist-
ent.116,130,131 Neither the AFFIRM,132 RACE,124 PIAF
(Pharmacologic Intervention in Atrial Fibrillation),125 nor
STAF (Strategies of Treatment of Atrial Fibrillation)126
studies found differences in quality of life with rhythm
control compared with rate control. Rhythm control in the
PIAF and HOT CAFE´ (How to Treat Chronic Atrial
Fibrillation)127 studies resulted in better exercise tolerance
than rate control, but this did not translate into improved
quality of life. Symptomatic improvement has been reported
after the maze procedure in patients with AF.133 Clinicians
must exercise judgment, however, in translating shifts in
quality of life in these selected populations to the sense of
well-being experienced by individual patients. Patients
with similar health status may experience an entirely differ-
ent quality of life, and treatment must be tailored to each
individual, depending on the nature, intensity, and fre-
quency of symptoms, patient preferences, comorbid con-
ditions, and the ongoing response to treatment.
Depending on symptoms, rate control may be reasonable
initial therapy in older patients with persistent AF who
have hypertension or heart disease. For younger individuals,
especially those with paroxysmal lone AF, rhythm control
may be a better initial approach. Often, medications that
exert both antiarrhythmic and rate-controlling effects are
required. Catheter ablation should be considered to main-
tain sinus rhythm in selected patients who failed to
respond to antiarrhythmic drug therapy.134
In patients with AF, the ventricular rate may accelerate
excessively during exercise even when it is well-controlled
at rest. In addition to allowing adequate time for ventricular
ﬁlling and avoiding rate-related ischemia, enhancement of
intraventricular conduction with rate reduction may result
in improved hemodynamics. It may be useful to evaluate
the heart rate response to submaximal or maximal exercise
or to monitor the rate over an extended period (e.g., by use
of 24-h Holter recording). The deﬁnition of adequate rate
control has been based primarily on short-term hemody-
namic beneﬁts and not well studied with respect to regu-
larity or irregularity of the ventricular response to AF,
quality of life, symptoms, or development of cardiomyopa-
thy. No standard method for assessment of heart rate
control has been established to guide the management of
patients with AF. Criteria for rate control vary with patient
age but usually involve achieving ventricular rates
between 60 and 80 beats per minute at rest and between
90 and 115 beats per minute during moderate exercise.
Patients who are symptomatic with rapid ventricular rates
during AF require prompt medical management, and cardio-
version should be considered if symptomatic hypotension,
angina, or HF is present. A sustained, uncontrolled tachy-
cardia may lead to deterioration of ventricular function
(tachycardia-related cardiomyopathy) that improves with
adequate rate control. Tachycardia-induced cardiomyopathy
Table 4 Trials comparing rate control and rhythm control strategies in patients with AF
Trial Reference Patients
(n)
AF duration Follow-up
(y)
Age
(mean y +SD)
Patients in SRa Clinical events (n)
Stroke/embolism Death
Rate Rhythm Rate Rhythm
AFFIRM (2002) 128 4060 b/NR 3.5 70+ 9 35% vs. 63% (at 5 y) 88/2027 93/2033 310/2027 356/2033
RACE (2002) 124 522 1 to 399 d 2.3 68+ 9 10% vs. 39% (at 2.3 y) 7/256 16/266 18/256 18/266
PIAF (2000) 130 252 7 to 360 d 1 61+ 10 10% vs. 56% (at 1 y) 0/125 2/127 2/125 2/127
STAF (2003) 126 200 6+3 mo 1.6 66+ 8 11% vs. 26% (at 2 y) 2/100 5/100 8/100 4/100
HOT CAFE´
(2004)
127 205 7 to 730 d 1.7 61+ 11 NR vs. 64% 1/101 3/104 1/101 3/104
aComparison between rate and rhythm control groups.
bApproximately one third of patients were enrolled with ﬁrst episode of atrial ﬁbrillation (AF).
AFFIRM indicates Atrial Fibrillation Follow-Up Investigation of Rhythm Management; ECV, internal or external electrical cardioversion; HOT CAFE´, How to
Treat Chronic Atrial Fibrillation; IA, quinidine, procainamide; IC, propafenone and/or ﬂecainide; NR, not reported; PIAF, Pharmacological Intervention in
Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for Persistent Atrial Fibrillation; SR, sinus rhythm; STAF, Strategies of Treatment of
Atrial Fibrillation; and TE, thromboembolism.
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Table 5 General characteristics of rhythm control and rate control trials in patients with AF
Trial Reference Patients (n) Mean age (y) Mean length
of follow-up (y)
Inclusion criteria Primary endpoint Patients reaching primary endpoint (n) p
Rate control Rhythm control
PIAF (2000) 130 252 61.0 1.0 Persistent AF (7 to 360 d) Symptomatic improvement 76/125 (60.8%) 70/127 (55.1%) 0.317
RACE (2002) 124 522 68.0 2.3 Persistent AF or ﬂutter for
less than 1 y and 1 to 2
cardioversions over 2 y
and oral anticoagulation
Composite: cardiovascular
death, CHF, severe
bleeding, PM implantation,
thromboembolic events,
severe adverse effects of
antiarrhythmic drugs
44/256 (17.2%) 60/266 (22.6%) 0.11
STAF (2002) 126 200 66.0 1.6 Persistent AF (longer than
4 wk and less than 2 y),
left atrial size greater
than 45 mm, CHF NYHA
II–IV, LVEF less than 45%
Composite: overall mortality,
cerebrovascular compli-
cations, CPR, embolic
events
10/100 (10.0%) 9/100 (9.0%) 0.99
AFFIRM (2002) 128 4060 69.7 3.5 Paroxysmal AF or persistent
AF, age 65 y or older, or
risk of stroke or death
All-cause mortality 310/2027 (25.9%) 356/2033 (26.7%) 0.08
HOT CAFE´ (2004) 127 205 60.8 1.7 First clinically overt
episode of persistent AF
(7 d or more and less
than 2 y), 50 to 75 y old
Composite; death, throm-
boembolic complications;
intracranial or other major
hemorrhage
1/101 (1.0%) 4/104 (3.9%) Greater
than 0.71
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial ﬁbrillation. Nat Clin Pract Cardiovasc Med 2005;2:514–21.129
AF indicates atrial ﬁbrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; CHF, congestive heart failure; CPR, cardiopulmonary resuscitation; HOT CAFE´, How to Treat Chronic Atrial
Fibrillation; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; PIAF, Pharmacological Intervention in Atrial Fibrillation; PM, pacemaker; RACE, Rate Control Versus Electrical Cardioversion
for Persistent Atrial Fibrillation; and STAF, Strategies of Treatment of Atrial Fibrillation.
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tends to resolve within 6 mo of rate or rhythm control; when
tachycardia recurs, LV ejection fraction declines and HF
develops over a shorter period, and this is associated with
a relatively poor prognosis.137
a. Pharmacological rate control during atrial ﬁbrillation
The functional refractory period of the AV node correlates
inversely with ventricular rate during AF, and drugs that
prolong the refractory period are generally effective for
rate control. There is no evidence that pharmacological
rate control has any adverse inﬂuence on LV function, but
bradycardia and heart block may occur as an unwanted
effect of beta blockers, amiodarone, digitalis glycosides,
or nondihydropyridine calcium channel antagonists, particu-
larly in patients with paroxysmal AF, especially the elderly.
When rapid control of the ventricular response to AF is
required or oral administration of medication is not feasible,
medication may be administered intravenously. Otherwise,
in hemodynamically stable patients with a rapid ventricular
response to AF, negative chronotropic medication may
be administered orally (Table 7). Combinations may be
necessary to achieve rate control in both acute and
chronic situations. Some patients develop symptomatic
bradycardia that requires permanent pacing. Nonpharmaco-
logical therapy should be considered when pharmacological
measures fail.
Special considerations in patients with the Wolff-Parkinson-
White syndrome. Intravenous administration of beta block-
ers, digitalis, adenosine, lidocaine, and nondihydropyridine
calcium channel antagonists, all of which slow conduction
across the AV node, is contraindicated in patients with the
WPW syndrome and tachycardia associated with ventricular
preexcitation because they can facilitate antegrade conduc-
tion along the accessory pathway during AF,2 resulting in
acceleration of the ventricular rate, hypotension, or ventri-
cular ﬁbrillation.62 When the arrhythmia is associated with
hemodynamic compromise, however, early direct-current
cardioversion is indicated. In hemodynamically stable
patients with preexcitation, type I antiarrhythmic agents
or amiodarone may be administered intravenously. Beta
blockers and calcium channel blockers are reasonable for
oral maintenance therapy.138
Pharmacological therapy to control heart rate in patients
with both atrial ﬁbrillation and atrial ﬂutter. A patient
treated with AV nodal blocking drugs whose ventricular
rate is well controlled during AF may experience a rise or
fall in rate if he or she develops atrial ﬂutter. This is also
true when antiarrhythmic agents such as propafenone or ﬂe-
cainide are used to prevent recurrent AF. These compounds
may increase the likelihood of 1:1 AV conduction during
atrial ﬂutter leading to a very rapid ventricular response.
Thus, when these agents are given for prophylaxis against
recurrent paroxysmal AF or atrial ﬂutter, AV nodal blocking
drugs should be routinely coadministered. An exception
may be patients with paroxysmal AF who have undergone
catheter ablation of the cavotricuspid isthmus to prevent
atrial ﬂutter.
b. Regulation of atrioventricular nodal conduction by
pacing
Because ventricular pacing prolongs the AV nodal refractory
period as a result of concealed retrograde penetration, it
eliminates longer ventricular cycles and may reduce the
number of short ventricular cycles related to rapid AV
conduction during AF. Pacing at approximately the mean
ventricular rate during spontaneous AV conduction can
regulate the ventricular rhythm during AF.139 This may be
useful for patients with marked variability in ventricular
rates or for those who develop resting bradycardia during
treatment with medication. In some patients, the hemody-
namic beneﬁt of revascularization may be offset by asyn-
chronous ventricular activation during right ventricular
pacing.
c. Atrioventricular nodal ablation
AV nodal ablation in conjunction with permanent pacemaker
implantation provides highly effective control of the heart
rate and improves symptoms in selected patients with
AF.140–143 In general, patients most likely to beneﬁt from
this strategy are those with symptoms or tachycardia-
mediated cardiomyopathy related to rapid ventricular
rate during AF that cannot be controlled adequately with
antiarrhythmic or negative chronotropic medications.
Meta-analyses of 21 studies published between 1989 and
1998 that included a total of 1181 patients concluded that
AV nodal ablation and permanent pacemaker implantation
signiﬁcantly improved cardiac symptoms, quality of life,
and healthcare utilization for patients with symptomatic
AF refractory to medical treatment.143 Catheter ablation
of inferior atrial inputs to the AV node slows the ventricular
Table 6 Comparison of adverse outcomes in rhythm control and rate control trials in patients with AF
Trial Reference Deaths of all
causes (n rate/
rhythm)
Deaths from
cardiovascular
causes
Deaths from
noncardiovascular
causes
Stroke Thromboembolic
events
Bleeding
RACE (2002) 124 36 18/18 ND ND 14/21 12/9
PIAF (2000) 130 4 1/1 1a ND ND ND
STAF (2003) 126 12 (8/4) 8/3 0/1 1/5 ND 8/11
AFFIRM (2002) 128 666 (310/356) 167/164 113/165 77/80 ND 107/96
HOT CAFE´ (2004) 127 4 (1/3) 0/2 1/1 0/3 ND 5/8
aTotal number of patients not reported.
Reprinted with permission from Pelargonio G, Prystowsky EN. Rate versus rhythm control in the management of patients with atrial ﬁbrillation. Nat Clin
Pract Cardiovasc Med 2005;2:514–21.129
AF indicates atrial ﬁbrillation; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management; HOT CAFE´, How to Treat Chronic Atrial
Fibrillation; ND, not determined; PIAF, Pharmacological Intervention in Atrial Fibrillation; RACE, Rate Control Versus Electrical Cardioversion for
Persistent Atrial Fibrillation; and STAF, Strategies of Treatment of Atrial Fibrillation.
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Table 7 Intravenous and orally administered pharmacological agents for heart rate control in patients with atrial ﬁbrillation
Drug Class/LOE
recommendation
Loading dose Onset Maintenance dose Major side effects
Acute setting
Heart rate control in patients without accessory pathway
Esmololab Class I, LOE C 500 mcg/kg IV over
1 min
5 min 60 to 200 mcg/kg/
min IV
# BP, HB, # HR,
asthma, HF
Metoprololb Class I, LOE C 2.5 to 5 mg IV bolus
over 2 min; up to
3 doses
5 min NA # BP, HB, # HR,
asthma, HF
Propranololb Class I, LOE C 0.15 mg/kg IV 5 min NA # BP, HB, # HR,
asthma, HF
Diltiazem Class I, LOE B 0.25 mg/kg IV over
2 min
2 to 7 min 5 to 15 mg/h IV # BP, HB, HF
Verapamil Class I, LOE B 0.075 to 0.15 mg/kg
IV over 2 min
3 to 5 min NA # BP, HB, HF
Heart rate control in patients with accessory pathwayd
Amiodaronece Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min
IV
# BP, HB, pulmonary
toxicity, skin discolor-
ation, hypothyroidism,
hyperthyroidism,
corneal deposits, optic
neuropathy, warfarin
interaction, sinus
bradycardia
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE B 0.25 mg IV each 2 h,
up to 1.5 mg
60 min or mored 0.125 to 0.375 mg
daily IV or orally
Digitalis toxicity, HB,
# HR
Amiodaronec Class IIa, LOE C 150 mg over 10 min Days 0.5 to 1 mg/min
IV
# BP, HB, pulmonary
toxicity, skin discolor-
ation, hypothyroidism,
hyperthyroidism,
corneal deposits, optic
neuropathy, warfarin
interaction, sinus
bradycardia
Non-acute setting and chronic maintenance therapy f
Heart rate control
Metoprololb Class I, LOE C Same as maintenance
dose
4 to 6 h 25 to 100 mg
twice a day,
orally
# BP, HB, # HR, asthma,
HF
Propranololb Class I, LOE C Same as maintenance
dose
60 to 90 min 80 to 240 mg
daily in divided
doses, orally
# BP, HB, # HR, asthma,
HF
Diltiazem Class I, LOE B Same as maintenance
dose
2 to 4 h 120 to 360 mg
daily in divided
doses; slow
release available,
orally
# BP, HB, HF
Verapamil Class I, LOE B Same as maintenance
dose
1 to 2 h 120 to 360 mg daily
in divided doses;
slow release
available, orally
# BP, HB, HF, digoxin
interaction
Heart rate control in patients with heart failure and without accessory pathway
Digoxin Class I, LOE C 0.5 mg by mouth daily 2 days 0.125 to 0.375 mg
daily, orally
Digitalis toxicity, HB,
# HR
Continued
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rate during AF and improves symptoms without pacemaker
implantation.144,145 This technique has several limitations,
however, including inadvertent complete AV block and a ten-
dency of ventricular rate to rise over the 6 mo following
ablation. Thus, AV nodal modiﬁcation without pacemaker
implantation is only rarely used.
Although the symptomatic beneﬁts of AV nodal ablation
are clear, limitations include the persistent need for anti-
coagulation, loss of AV synchrony, and lifelong pacemaker
dependency. There is also a ﬁnite risk of sudden death due
to torsades de pointes or ventricular ﬁbrillation.146
Patients with abnormalities of diastolic ventricular compli-
ance who depend on AV synchrony to maintain cardiac
output, such as those with HCM or hypertensive heart
disease, may experience persistent symptoms after AV
nodal ablation and pacemaker implantation. Hence,
patients should be counseled regarding each of these con-
siderations before proceeding with this irreversible
measure.
Patients with normal LV function or reversible LV dysfunc-
tion undergoing AV nodal ablation are most likely to beneﬁt
from standard AV nodal ablation and pacemaker implan-
tation. For those with impaired LV function not due to tachy-
cardia, a biventricular pacemaker with or without
deﬁbrillator capability should be considered. Upgrading to
a biventricular device should be considered for patients
with HF and a right ventricular pacing system who have
undergone AV node ablation.147
2. Preventing thromboembolism
a. Risk stratiﬁcation
Epidemiological data. In a small, retrospective, population-
based study in Olmsted County, Minnesota, over 3 decades,
the 15-y cumulative stroke rate in people with lone AF
(deﬁned as those younger than 60 y with no clinical history
or echocardiographic signs of cardiopulmonary disease)
was 1.3%.5 In the SPAF (Stroke Prevention in Atrial
Fibrillation III) studies, the annualized rate of ischemic
stroke during aspirin treatment was similar in those with
paroxysmal (3.2%) and permanent (3.3%) AF.148 Those with
prior stroke or TIA have a rate of subsequent stroke of 10%
to 12% per year when treated with aspirin, and these
patients beneﬁt substantially from adjusted-dose oral anti-
coagulation.149 In addition to prior thromboembolism, HF,
hypertension, increasing age, and diabetes mellitus have
consistently emerged as independent risk factors for
ischemic stroke associated with nonvalvular AF.96 Other
factors, such as female gender, systolic blood pressure
over 160 mm Hg, and LV dysfunction, have been variably
linked to stroke.96 The relative risk for ischemic stroke
associated with speciﬁc clinical features, derived from a col-
laborative analysis of participants given no antithrombotic
therapy in the control groups of 5 randomized trials, is dis-
played in Table 8. In patients with nonvalvular AF, prior
stroke or TIA is the strongest independent predictor of
stroke, signiﬁcantly associated with stroke in all 6 studies
in which it was evaluated, with incremental relative risk
between 1.9 and 3.7 (averaging approximately 3.0). All
patients with prior stroke or TIA require anticoagulation
unless contraindications exist in a given patient. Patient
age is a consistent independent predictor of stroke
(Figure 3), but older people are also at increased risk for
anticoagulant-related bleeding.150 Special consideration of
these older patients is therefore a critical aspect of effec-
tive stroke prophylaxis.151
Echocardiography and risk stratiﬁcation. Echocardiography
is valuable to deﬁne the origin of AF (e.g., detecting rheu-
matic mitral valve disease or HCM) and may add information
useful in stratifying thromboembolic risk. Among high-risk
AF patients, impaired LV systolic function on transthoracic
echocardiography, thrombus, dense spontaneous echo con-
trast or reduced velocity of blood ﬂow in the LAA, and
complex atheromatous plaque in the thoracic aorta on TEE
have been associated with thromboembolism, and oral
anticoagulation effectively lowers the risk of stroke in AF
patients with these features. LA diameter and ﬁbrocalciﬁc
endocardial abnormalities have been less consistently
associated with thromboembolism. Whether the absence
of these echocardiographic abnormalities identiﬁes a
Table 7 Continued
Drug Class/LOE
recommendation
Loading dose Onset Maintenance dose Major side effects
Amiodaronec Class IIb, LOE C 800 mg daily for 1 wk,
orally; 600 mg daily
for 1 wk, orally;
400 mg daily for 4
to 6 wk, orally
1 to 3 wk 200 mg daily, orally # BP, HB, pulmonary
toxicity, skin discolor-
ation, hypothyroidism,
hyperthyroidism,
corneal deposits, optic
neuropathy, warfarin
interaction, sinus
bradycardia
aOnset is variable and some effect occurs earlier.
bOnly representative members of the type of beta-adrenergic antagonist drugs are included in the table, but other, similar agents could be used for this
indication in appropriate doses. Beta blockers are grouped in an order preceding the alphabetical listing of drugs.
cAmiodarone can be useful to control the heart rate in patients with atrial ﬁbrillation (AF) when other measures are unsuccessful or contraindicated.
dConversion to sinus rhythm and catheter ablation of the accessory pathway are generally recommended; pharmacological therapy for rate control may be
appropriate in certain patients.
eIf rhythm cannot be converted or ablated and rate control is needed, intravenous (IV) amiodarone is recommended.
fAdequacy of heart rate control should be assessed during physical activity as well as at rest.
#BP indicates hypotension; # HR, bradycardia; HB, heart block; HF, heart failure; LOE, level of evidence; and NA, not applicable.
2000 ACC/AHA/ESC Guidelines
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low-risk group of patients who could safely avoid anticoagu-
lation has not been established, limiting the value of echo-
cardiography as a prime determinant of the need for
chronic anticoagulation in patients with AF.
Several clinical schemes have been proposed to stratify
the risk of ischemic stroke in patients with AF, based on ana-
lyses of prospectively monitored cohorts of participants in
clinical trials in which antithrombotic therapy was con-
trolled. Other criteria have been developed by expert con-
sensus to classify patients into low-, intermediate-, and
high-risk groups. Still others have used recursive partitioning
and other techniques to identify low-risk patients. The
CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes,
Stroke [Doubled]) integrates elements from several of
these schemes and is based on a point system in which 2
points are assigned for a history of stroke or TIA and 1
point each is assigned for age over 75 y and a history of
hypertension, diabetes, or recent HF (Table 9).152,153 The
predictive value of this scoring system was evaluated in
1733 Medicare beneﬁciaries with nonvalvular AF between
the ages of 65 and 95 y who were not given warfarin at hos-
pital discharge. Although high scores were associated with
an increased stroke rate in this elderly cohort, few patients
had a score of 5 or more or a score of 0.
Although these schemes for stratiﬁcation of stroke risk
identify patients who beneﬁt most and least from anticoagu-
lation, the threshold for use of anticoagulation is controver-
sial. Opinion is particularly divided about anticoagulation for
those at intermediate risk (stroke rate 3% to 5% per year).
Some advocate the routine use of anticoagulation in those
with stroke rates in this range,154 whereas others favor
selective anticoagulation of patients at intermediate risk,
with weight given to individual bleeding risks and patient
preferences.24 The threshold of beneﬁt at which AF patients
choose anticoagulation varies; some at intermediate risk
elect anticoagulation, whereas others do not.155 Our rec-
ommendations for antithrombotic therapy in patients with
AF are summarized in Table 10.
The risk of thromboembolism is not as well established for
atrial ﬂutter as it is for AF but is generally estimated as
higher than that for patients with sinus rhythm and less
than that for those with persistent or permanent AF.
Although the overall thromboembolic risk associated with
atrial ﬂutter may be somewhat lower than with AF,156 it
seems prudent to estimate risk by the use of similar stratiﬁ-
cation criteria for both arrhythmias until more robust data
become available.
b. Antithrombotic strategies for prevention of ischemic
stroke and systemic embolism
Before 1990, antithrombotic therapy for prevention of
ischemic stroke and systemic embolism in patients with AF
was limited mainly to those with rheumatic heart disease
or prosthetic heart valves.23 Anticoagulation was also
accepted therapy for patients who had sustained ischemic
stroke to prevent recurrence but was often delayed to
avoid hemorrhagic transformation. Some advocated anti-
coagulation of patients with thyrotoxicosis or other con-
ditions associated with cardiomyopathy. Since then, 24
randomized trials involving patients with nonvalvular AF
have been published, including 20 012 participants with
an average follow-up of 1.6 y, a total exposure of about
32 800 patient-y.
Anticoagulation with vitamin K antagonist agents. Five
large randomized trials published between 1989 and 1992
evaluated oral anticoagulation mainly for primary preven-
tion of thromboembolism in patients with nonvalvular
AF157–163 (Figure 4). A sixth trial focused on secondary pre-
vention among patients who had survived nondisabling
stroke or cerebral TIA.164 Meta-analysis according to the
principle of intention to treat showed that adjusted-dose
oral anticoagulation is highly efﬁcacious for prevention of
all stroke (both ischemic and hemorrhagic), with a risk
reduction of 61% (95% CI 47% to 71%) versus placebo165
(Figure 4). The duration of follow-up was generally
between 1 and 2 y; the longest was 2.2 y, whereas in clinical
practice, the need for antithrombotic therapy in patients
with AF typically extends over much longer periods.
All reported trials excluded patients considered at high
risk of bleeding. Patient age and the intensity of anticoagu-
lation are the most powerful predictors of major bleed-
ing.166–169 Trial participants, at an average age of 69 y,
were carefully selected and managed, however, and it is
unclear whether the relatively low observed rates of
major hemorrhage also apply to patients with AF in clinical
practice, who have a mean age of about 75 y and less closely
regulated anticoagulation therapy.
Table 8 Risk factors for ischemic stroke and systemic embolism
in patients with nonvalvular atrial ﬁbrillation
Risk factors Relative risk
Previous stroke or TIA 2.5
Diabetes mellitus 1.7
History of hypertension 1.6
Heart failure 1.4
Advanced age (continuous, per decade) 1.4
Data derived from collaborative analysis of 5 untreated control
groups in primary prevention trials.17 As a group, patients with nonvalvu-
lar atrial ﬁbrillation (AF) carry about a 6-fold increased risk of throm-
boembolism compared with patients in sinus rhythm. Relative risk
refers to comparison of patients with AF to patients without these
risk factors.
TIA indicates transient ischemic attack.
Figure 3 Stroke rates in relation to age among patients in untreated control
groups of randomized trials of antithrombotic therapy. Data are from the
Atrial Fibrillation Investigators. Risk factors for stroke and efﬁcacy of anti-
thrombotic therapy in atrial ﬁbrillation. Analysis of pooled data from ﬁve
randomized controlled trials. Arch Intern Med 1994;154:1449–1457.17
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The target intensity of anticoagulation involves a balance
between prevention of ischemic stroke and avoidance of
hemorrhagic complications (Figure 5). Targeting the lowest
adequate intensity of anticoagulation to minimize the risk
of bleeding is particularly important for elderly AF patients.
Maximum protection against ischemic stroke in AF is prob-
ably achieved at an INR range of 2.0 to 3.0.170 Despite anti-
coagulation of more elderly patients with AF, rates of
intracerebral hemorrhage are considerably lower than in
the past, typically between 0.1% and 0.6% in contemporary
reports. This may reﬂect lower anticoagulation intensity,
more careful dose regulation, or better control of
hypertension.171–173
Aspirin for antithrombotic therapy in patients with atrial
ﬁbrillation. Aspirin offers only modest protection against
stroke for patients with AF157,161,164,174–180 (Figure 6).
Meta-analysis of 5 randomized trials showed a stroke
reduction of 19% (95% CI ¼ 2% to 34%).165 Aspirin may be
more efﬁcacious for AF patients with hypertension or dia-
betes181 and for reduction of noncardioembolic versus cardio-
embolic ischemic strokes in AF patients.72 Cardioembolic
strokes are, on average, more disabling than noncardioem-
bolic strokes.92 Aspirin appears to prevent nondisabling
strokes more than disabling strokes.165 Thus, the greater
the risk of disabling cardioembolic stroke in a population
of patients with AF, the less protection is afforded by
aspirin.92
Combining anticoagulant and platelet-inhibitor therapy.
Combinations of oral anticoagulants plus antiplatelet
agents have not generally shown reduced risks of hemor-
rhage or augmented efﬁcacy over adjusted-dose anticoagu-
lation alone. Combining aspirin with an oral anticoagulant
at higher intensities may accentuate intracranial hemor-
rhage, particularly in elderly AF patients.183 For most
patients with AF who have stable CAD, warfarin anticoagula-
tion alone (target INR 2.0 to 3.0) should provide satisfactory
antithrombotic prophylaxis against both cerebral and myo-
cardial ischemic events.
Platelet-inhibitor drugs are particularly valuable for pre-
vention of recurrent myocardial ischemia in patients under-
going percutaneous coronary intervention, but no adequate
studies have been published that speciﬁcally address this
issue in patients who also require chronic anticoagulation
because of AF. It is the consensus of the authors of these
guidelines that the most important agent for the mainten-
ance of coronary and stent patency is the thienopyridine
derivative clopidogrel and that the addition of aspirin to
the chronic anticoagulant regimen contributes more risk
than beneﬁt. Although it is usually necessary to interrupt
or reduce anticoagulation to prevent bleeding at the site of
peripheral arterial puncture, the vitamin K antagonist
should be resumed as soon as possible after the procedure
and the dose adjusted to achieve an INR in the therapeutic
range. Aspirin may be given temporarily during the hiatus,
but the maintenance regimen should then consist of the
Table 9 Stroke risk in patients with nonvalvular AF not treated
with anticoagulation according to the CHADS2 index
CHADS2 risk criteria Score
Prior stroke or TIA 2
Age .75 y 1
Hypertension 1
Diabetes mellitus 1
Heart failure 1
Patients (N ¼ 1733) Adjusted stroke rate
(%/y)a (95% CI)
CHADS2
score
120 1.9 (1.2 to 3.0) 0
463 2.8 (2.0 to 3.8) 1
523 4.0 (3.1 to 5.1) 2
337 5.9 (4.6 to 7.3) 3
220 8.5 (6.3 to 11.1) 4
65 12.5 (8.2 to 17.5) 5
5 18.2 (10.5 to 27.4) 6
aThe adjusted stroke rate was derived from multivariate analysis assum-
ing no aspirin usage. Data are from van Walraven WC, Hart RG, Wells GA,
et al. A clinical prediction rule to identify patients with atrial ﬁbrillation
and a low risk for stroke while taking aspirin. Arch Intern Med 2003;163:
936–43153; and Gage BF, Waterman AD, Shannon W, et al. Validation of
clinical classiﬁcation schemes for predicting stroke: results from the
National Registry of Atrial Fibrillation. JAMA 2001;285:2864–70.152
AF indicates atrial ﬁbrillation; CHADS2, Cardiac Failure, Hypertension,
Age, Diabetes, and Stroke (Doubled); CI, conﬁdence interval; and TIA,
transient ischemic attack.
Table 10 Antithrombotic therapy for patients with atrial ﬁbrillation
Risk category Recommended therapy
No risk factors Aspirin, 81 to 325 mg daily
One moderate-risk factor Aspirin, 81 to 325 mg daily, or warfarin
(INR 2.0 to 3.0, target 2.5)
Any high-risk factor or more than
1 moderate-risk factor
Warfarin (INR 2.0 to 3.0, target 2.5)a
Less validated or weaker risk factors Moderate-risk factors High-risk factors
Female gender Age greater than or equal to 75 y Previous stroke, TIA or embolism
Age 65 to 74 y Hypertension Mitral stenosis
Coronary artery disease Heart failure Prosthetic heart valvea
Thyrotoxicosis LV ejection fraction 35% or less
Diabetes mellitus
aIf mechanical valve, target international normalized ratio (INR) greater than 2.5.
INR indicates international normalized ratio; LV, left ventricular; and TIA, transient ischemic attack.
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combination of clopidogrel, 75 mg daily, plus warfarin (INR
2.0 to 3.0) for 9 to 12 mo, after which warfarin may be con-
tinued as monotherapy in the absence of a subsequent coron-
ary event.
Low-molecular-weight heparins. The use of low-molecular-
weight heparin instead of unfractionated heparin in patients
with AF is based largely on extrapolation from venous
thromboembolic disease states and from limited observa-
tional studies.184 In general, low-molecular-weight heparins
have several pharmacological advantages over unfraction-
ated heparin. These include a longer half-life, more predict-
able bioavailability (greater than 90% after subcutaneous
injection), predictable clearance (enabling once- or twice-
daily subcutaneous administration), and a predictable
antithrombotic response based on body weight, which
permits ﬁxed-dose treatment without laboratory monitoring
except under special circumstances such as obesity, renal
insufﬁciency, or pregnancy.185 The favorable properties of
low-molecular-weight heparins may simplify the treatment
of AF in acute situations and shorten or eliminate the need
for hospitalization to initiate anticoagulation. Self-
administration of low-molecular-weight heparins out of hos-
pital by patients with AF undergoing elective cardioversion
is a promising approach that may result in cost savings.186
Interruption of anticoagulation for diagnostic or thera-
peutic procedures. From time to time, it may be necessary
to interrupt oral anticoagulant therapy in preparation for
elective surgical procedures. In patients with mechanical
prosthetic heart valves, it is generally appropriate to substi-
tute unfractionated or low-molecular-weight heparin to
prevent thrombosis.187 In patients with AF who do not
have mechanical valves, however, based on extrapolation
from the annual rate of thromboembolism in patients with
nonvalvular AF, it is the consensus of the Writing Group
that anticoagulation may be interrupted for a period of up
to 1 wk for surgical or diagnostic procedures that carry a
risk of bleeding without substituting heparin. In high-risk
patients (particularly those with prior stroke, TIA, or sys-
temic embolism), or when a series of procedures requires
interruption of oral anticoagulant therapy for longer
periods, unfractionated or low-molecular-weight heparin
may be administered intravenously or subcutaneously.
c. Nonpharmacological approaches to prevention of
thromboembolism
An emerging option for patients with AF who cannot safely
undergo anticoagulation, not yet sufﬁciently investigated
to allow general clinical application, is obliteration of the
LAA to remove a principal nidus of thrombus formation.188
In addition to direct surgical amputation or truncation of
appendage, several methods are under development to
achieve this with intravascular catheters or transpericardial
approaches.189 The efﬁcacy of these techniques is presum-
ably related to the completeness and permanence of elimin-
ation of blood ﬂow into and out of the LAA. This has been
demonstrated by TEE at the time of intervention, but the
durability of the effect has not been conﬁrmed by sub-
sequent examinations over several years. Whether mechan-
ical measures intended to prevent embolism from
thrombotic material in the LAA will prove comparably effec-
tive and safer than anticoagulation for some patients
remains to be established.190
3. Cardioversion of atrial ﬁbrillation
Cardioversion may be performed electively to restore sinus
rhythm in patients with persistent AF. The need for cardio-
version may be immediate when the arrhythmia is the
main factor responsible for acute HF, hypotension, or
worsening of angina pectoris in a patient with CAD.
Nevertheless, cardioversion carries a risk of thromboembo-
lism unless anticoagulation prophylaxis is initiated before
Figure 5 Adjusted odds ratios for ischemic stroke and intracranial bleeding
in relation to intensity of anticoagulation. Modiﬁed with permission from
Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients
taking warfarin. Ann Intern Med 1994;120:897–902.166 Data from Ode´n A,
Fahle´n M, Hart RG. Optimal INR for prevention of stroke and death in atrial
ﬁbrillation: a critical appraisal. Thromb Res 2006;117:493–9.167
Figure 4 Antithrombotic therapy for prevention of stroke (ischemic and
hemorrhagic) in patients with nonvalvular atrial ﬁbrillation. Adjusted-dose
warfarin compared with placebo (six random trials). Modiﬁed with permission
from Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to
prevent stroke in patients with atrial ﬁbrillation: a meta-analysis. Ann
Intern Med 1999;131:492–501.165 AFASAK indicates Copenhagen Atrial
Fibrillation, Aspirin, Anticoagulation; BAATAF, Boston Area Anticoagulation
Trial for Atrial Fibrillation; CAFA, Canadian Atrial Fibrillation
Anticoagulation; EAFT, European Atrial Fibrillation Trial; SPAF, Stroke
Prevention in Atrial Fibrillation; and SPINAF, Stroke Prevention in
Nonrheumatic Atrial Fibrillation.
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the procedure, and this risk is greatest when the arrhythmia
has been present more than 48 h.
Cardioversion may be achieved by means of drugs or elec-
trical shocks. Drugs were commonly used before direct-
current cardioversion became a standard procedure. The
development of new drugs has increased the popularity of
pharmacological cardioversion, but the disadvantages
include the risk of drug-induced torsades de pointes or
other serious arrhythmias. Moreover, pharmacological cardio-
version is less effective than direct-current cardioversion
when biphasic shocks are used. The disadvantage of electri-
cal cardioversion is that it requires conscious sedation or
anesthesia, which pharmacological cardioversion does not.
There is no evidence that the risk of thromboembolism or
stroke differs between pharmacological and electrical
methods of cardioversion. The recommendations for anti-
coagulation are therefore the same for both methods, as
outlined in Section I.C.2, Preventing thromboembolism.
Cardioversion in patients with AF following recent heart
surgery or MI is addressed later (see Section I.C.5, Special
considerations).
a. Pharmacological cardioversion
The quality of evidence available to gauge the effectiveness
of pharmacological cardioversion is limited by small
samples, lack of standard inclusion criteria (many studies
include both patients with AF and those with atrial
ﬂutter), variable intervals from drug administration to
assessment of outcome, and arbitrary dose selection.
Although pharmacological and direct-current cardioversion
have not been compared directly, pharmacological
approaches appear simpler but are less efﬁcacious. The
major risk is related to the toxicity of antiarrhythmic
drugs. In developing these guidelines, placebo-controlled
trials of pharmacological cardioversion in which drugs
were administered over short periods of time speciﬁcally
to restore sinus rhythm have been emphasized. Trials in
which the control group was given another antiarrhythmic
drug have, however, been considered as well.
Pharmacological cardioversion seems most effective when
initiated within 7 d after the onset of an episode of AF.191,192
A majority of these patients have a ﬁrst-documented
episode of AF or an unknown pattern of AF at the time of
treatment. (See Section III, Classiﬁcation.) A large pro-
portion of patients with recent-onset AF experience spon-
taneous cardioversion within 24 to 48 h.193 Spontaneous
conversion is less frequent in patients with AF of longer
than 7-d duration, and the efﬁcacy of pharmacological car-
dioversion is markedly reduced in these patients as well.
Pharmacological cardioversion may accelerate restoration
of sinus rhythm in patients with recent-onset AF, but the
advantage over placebo is modest after 24 to 48 h, and
drug therapy is much less effective in patients with persist-
ent AF. Some drugs have a delayed onset of action, and con-
version may not occur for several days after initiation of
treatment.194 Drug treatment abbreviated the interval to
cardioversion compared with placebo in some studies
without affecting the proportion of patients who remained
in sinus rhythm after 24 h.195 A potential interaction of anti-
arrhythmic drugs with vitamin K antagonist oral anticoagu-
lants, increasing or decreasing the anticoagulant effect, is
an issue whenever these drugs are added or withdrawn
from the treatment regimen. The problem is ampliﬁed
when anticoagulation is initiated in preparation for elective
cardioversion. Addition of an antiarrhythmic drug to
enhance the likelihood that sinus rhythm will be restored
and maintained may perturb the intensity of anticoagulation
beyond the intended therapeutic range, raising the risk of
bleeding or thromboembolic complications.
A summary of recommendations concerning the use of
pharmacological agents and recommended doses for cardio-
version of AF is presented in Tables 11–13. Algorithms
for pharmacological management of AF are given in
Figures 7–10. Throughout this document, reference is made
Figure 6 Antithrombotic therapy for prevention of stroke (ischemic and hemorrhagic) in patients with nonvalvular atrial ﬁbrillation: warfarin compared with
aspirin and aspirin compared with placebo. Modiﬁed with permission from Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke
in patients with atrial ﬁbrillation: a meta-analysis. Ann Intern Med 1999;131:492–501.165 AFASAK indicates Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation; EAFT, European Atrial Fibrillation Trial; ESPS, European Stroke Prevention Study; LASAF, Low-Dose Aspirin, Stroke, Atrial Fibrillation; UK-TIA,
United Kingdom Transient Ischaemic Attack Aspirin Trial; PATAF, Prevention of Arterial Thromboembolism in Atrial Fibrillation; SPAF, Stroke Prevention in
Atrial Fibrillation; and SPINAF, Stroke Prevention in Nonrheumatic Atrial Fibrillation.
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to the Vaughan Williams classiﬁcation of antiarrhythmic
drugs,196 modiﬁed to include drugs that became available
after the original classiﬁcation was developed (Table 14).
The recommendations given in this document are based on
published data and do not necessarily adhere to the regu-
lations and labeling requirements of governmental agencies.
These antiarrhythmic drugs have been approved by federal
regulatory agencies in the United States and/or Europe for
clinical use, but their use for the treatment of AF has not
been approved in all cases. Furthermore, not all agents are
approved for use in all countries.
4. Pharmacological agents to maintain sinus rhythm
a. Agents with proven efﬁcacy to maintain sinus rhythm
Thirty-six controlled trials evaluating 7 antiarrhythmic drugs
for the maintenance of sinus rhythm in patients with parox-
ysmal or persistent AF, 14 controlled trials of drug prophy-
laxis involving patients with paroxysmal AF, and 22 trials of
drug prophylaxis for maintenance of sinus rhythm in patients
with persistent AF were identiﬁed. Comparative data are
not sufﬁcient to permit subclassiﬁcation by drug or etiology.
Individual drugs and doses for maintenance of sinus rhythm
are given in Table 15. It should be noted that any membrane
active agent may cause proarrhythmia.
b. Out-of-hospital initiation of antiarrhythmic drugs in
patients with atrial ﬁbrillation
A frequent issue related to pharmacological cardioversion of
AF is whether to initiate antiarrhythmic drug therapy in hos-
pital or on an outpatient basis. The major concern is the
potential for serious adverse effects, including torsades de
pointes. With the exception of those involving low-dose
oral amiodarone,234 virtually all studies of pharmacological
cardioversion have involved hospitalized patients.
However, 1 study251 provided a clinically useful approach
with out-of-hospital patient-controlled conversion using
class IC drugs.
The ‘pill-in-the-pocket’ strategy consists of the self-
administration of a single oral dose of drug shortly after
the onset of symptomatic AF to improve quality of life,
decrease hospital admission, and reduce cost.252
Recommendations for out-of-hospital initiation or intermit-
tent use of antiarrhythmic drugs differ for patients with par-
oxysmal and persistent AF. In patients with paroxysmal AF,
the aims are to terminate an episode or to prevent recur-
rence. In patients with persistent AF, the aims are to
achieve pharmacological cardioversion of AF, obviating the
need for direct-current cardioversion, or to enhance the
success of direct-current cardioversion by lowering the deﬁ-
brillation threshold and prevent early recurrence of AF.
In patients with lone AF without structural heart disease,
class IC drugs may be initiated on an outpatient basis. For
other selected patients without sinus or AV node dysfunc-
tion, bundle-branch block, QT-interval prolongation, the
Brugada syndrome, or structural heart disease,
‘pill-in-the-pocket’ administration of propafenone and ﬂe-
cainide outside the hospital becomes an option once treat-
ment has proved safe in hospital, given the relative safety
(lack of organ toxicity and low estimated incidence of proar-
rhythmia).253–255 Before these agents are initiated,
however, a beta blocker or nondihydropyridine calcium
channel antagonist is generally recommended to prevent
rapid AV conduction in the event of atrial ﬂutter.256,257
Unless AV node conduction is impaired, a short-acting beta
blocker or nondihydropyridine calcium channel antagonist
should be given at least 30 min before administration of a
type IC antiarrhythmic agent to terminate an acute
episode of AF, or the AV nodal blocking agents should be
prescribed as continuous background therapy. Because
termination of paroxysmal AF may be associated with brady-
cardia due to sinus node or AV node dysfunction, an initial
conversion trial should be undertaken in hospital before a
patient is declared ﬁt for outpatient ‘pill-in-the pocket’
use of ﬂecainide or propafenone for conversion of sub-
sequent recurrences of AF. Table 16 lists other factors
associated with proarrhythmic toxicity to class IC agents.
It should be noted that these include female gender.
Few prospective data are available on the relative safety
of initiating antiarrhythmic drug therapy in the outpatient
versus inpatient setting, and the decision to initiate
therapy out of hospital should be carefully individualized.
The ‘pill-in-the pocket’ approach appears feasible and
Table 11 Recommendations for pharmacological cardioversion of atrial ﬁbrillation of up to 7-d duration
Druga Route of
administration
Class of
recommendation
Level of
evidence
References
Agents with proven efﬁcacy
Dofetilide Oral I A 197–202
Flecainide Oral or intravenous I A 191, 203–210
Ibutilide Intravenous I A 211–216
Propafenone Oral or intravenous I A 191, 193, 195, 207, 210, 217–227, 255
Amiodarone Oral or intravenous IIa A 194, 206, 217, 228–235
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 247
Procainamide Intravenous IIb B 211, 213, 239
Quinidine Oral IIb B 195, 203, 225, 230, 236–238, 273
Should not be administered
Digoxin Oral or intravenous III A 195, 207, 227, 231, 241, 245
Sotalol Oral or intravenous III A 214, 237, 238, 242, 246
aThe doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within
each category of recommendation and level of evidence.
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safe for selected patients with AF, but the safety of this
approach without previous inpatient evaluation remains
uncertain.
As long as the baseline uncorrected QT interval is less than
460 ms, serum electrolytes are normal, and risk factors
associated with class III drug-related proarrhythmia are con-
sidered (Table 16), sotalol may be initiated in outpatients
with little or no heart disease. It is safest to start sotalol
when the patient is in sinus rhythm. Amiodarone can also
usually be given safely on an outpatient basis, even in
patients with persistent AF, because it causes minimal
depression of myocardial function and has low proarrhyth-
mic potential,258 but in-hospital loading may be necessary
for earlier restoration of sinus rhythm in patients with HF
or other forms of hemodynamic compromise related to AF.
Loading regimens typically call for administration of
600 mg daily for 4 wk258 or 1 g daily for 1 wk,232 followed
by lower maintenance doses. Amiodarone, class IA or IC
agents, or sotalol can be associated with bradycardia requir-
ing permanent pacemaker implantation259; this is more
frequent with amiodarone, and amiodarone-associated bra-
dycardia is more common in women than in men. Quinidine,
procainamide, and disopyramide should not be started out
of hospital and out-of-hospital initiation of dofetilide is
not currently permitted. Transtelephonic monitoring or
other methods of ECG surveillance may be used to monitor
cardiac rhythm and conduction as pharmacological anti-
arrhythmic therapy is initiated in patients with AF.
Speciﬁcally, the PR interval (when ﬂecainide, propafenone,
sotalol, or amiodarone are used), QRS duration (with ﬂecai-
nide or propafenone), and QT interval (with dofetilide,
sotalol, amiodarone, or disopyramide) should be measured.
As a general rule, antiarrhythmic drugs should be started
at a relatively low dose and titrated based on response, and
the ECG should be reassessed after each dose change. The
heart rate should be monitored at approximately weekly
intervals, either by checking the pulse rate, by use of an
event recorder, or by ECG tracings obtained in the ofﬁce.
The dose of other medication for rate control should be
reduced when the rate slows after initiation of amiodarone
and stopped if the rate slows excessively. Concomitant drug
therapies should be monitored closely, and both the patient
and the physician should be alert to possible deleterious
interactions. The doses of digoxin and warfarin, in particu-
lar, should usually be reduced upon initiation of amiodarone
in anticipation of the rises in serum digoxin levels and INR
that typically occur.
5. Direct-current cardioversion of atrial ﬁbrillation and
atrial ﬂutter
a. Technical and procedural aspects
Direct-current cardioversion involves delivery of an electri-
cal shock synchronized with the intrinsic activity of the
heart by sensing the R wave of the ECG to ensure that elec-
trical stimulation does not occur during the vulnerable
phase of the cardiac cycle.136 Direct-current cardioversion
is used to normalize all abnormal cardiac rhythms except
ventricular ﬁbrillation. The term ‘deﬁbrillation’ implies an
asynchronous discharge, which is appropriate for correction
of ventricular ﬁbrillation because R-wave synchronization is
not feasible, but not for AF.
Successful cardioversion of AF depends on the underlying
heart disease and the current density delivered to the atrial
myocardium. Current may be delivered through external
chest wall electrodes or through an internal cardiac elec-
trode. Although the latter technique has been considered
superior to external countershocks in obese patients and in
patients with obstructive lung disease, it has not been
widely applied. The frequency of recurrent AF does not
differ between the 2 methods.135,260
Cardioversion should be performed with the patient under
adequate general anesthesia in a fasting state. Short-acting
anesthetic drugs or agents that produce conscious sedation
are preferred to enable rapid recovery after the procedure;
overnight hospitalization is seldom required.261 The electric
shock should be synchronized with the QRS complex, trig-
gered by monitoring the R wave with an appropriately
selected ECG lead that also clearly displays atrial activation
to facilitate assessment of outcome. In 64 patients randomly
assigned to initial monophasic waveform energies of 100,
200, or 360 J, high initial energy was signiﬁcantly more
effective than low levels (immediate success rates 14%
Table 12 Recommendations for pharmacological cardioversion of atrial ﬁbrillation present for more than 7 d
Druga Route of
administration
Recommendation
class
Level of
evidence
References
Agents with proven efﬁcacy
Dofetilide Oral I A 197–202
Amiodarone Oral or intravenous IIa A 194, 206, 217, 228–235
Ibutilide Intravenous IIa A 211–216
Less effective or incompletely studied agents
Disopyramide Intravenous IIb B 247
Flecainide Oral IIb B 191, 203–210
Procainamide Intravenous IIb C 211, 213, 239
Propafenone Oral or intravenous IIb B 191, 193, 195, 207, 210, 217–227,
248, 255
Quinidine Oral IIb B 195, 203, 225, 230, 236–238, 273
Should not be administered
Digoxin Oral or intravenous III B 195, 207, 227, 231, 241–243, 245
Sotalol Oral or intravenous III B 214, 237, 238, 242, 246
aThe doses of medications used in these studies may not be the same as those recommended by the manufacturers. Drugs are listed alphabetically within
each category by class and level of evidence.
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Table 13 Recommended doses of drugs proven effective for pharmacological cardioversion of atrial ﬁbrillation
Druga Route of administration Dosageb Potential adverse effects References
Amiodarone Oral Inpatient: 1.2 to 1.8 g per day in divided dose until 10 g
total, then 200 to 400 mg per day maintenance or
30 mg/kg as single dose
Hypotension, bradycardia, QT
prolongation, torsades de pointes
(rare), GI upset, constipation,
phlebitis (IV)
194, 206, 217, 228–236, 250
Outpatient: 600 to 800 mg per day divided dose until
10 g total, then 200 to 400 mg per day maintenance
Intravenous/oral 5 to 7 mg/kg over 30 to 60 min, then 1.2 to 1.8 g per day
continuous IV or in divided oral doses until 10 g total,
then 200 to 400 mg per day maintenance
Dofetilide Oral Creatinine clearance
(mL/min)
Dose
(mcg BID)
More than 60 500 QT prolongation, torsades de pointes;
adjust dose for renal function,
body size and age
197–202
40 to 60 250
20 to 40 125
Less than 20 Contraindicated
Flecainide Oral
Intravenous
200 to 300 mgc
1.5 to 3.0 mg/kg over 10 to 20 minc
Hypotension, atrial ﬂutter with high
ventricular rate
191, 203–210
Ibutilide Intravenous 1 mg over 10 min; repeat 1 mg when necessary QT prolongation, torsades de pointes 211–216
Propafenone Oral 600 mg Hypotension, atrial ﬂutter with high
ventricular rate
191, 193, 195, 207, 210,
217-227, 248, 255
Intravenous 1.5 to 2.0 mg/kg over 10 to 20 minc
Quinidined Oral 0.75 to 1.5 g in divided doses over
6 to 12 h, usually with a rate-slowing drug
QT prolongation, torsades de pointes,
GI upset, hypotension
195, 203, 225, 230, 236-238
aDrugs are listed alphabetically.
bDosages given in the table may differ from those recommended by the manufacturers.
cInsufﬁcient data are available on which to base speciﬁc recommendations for the use of one loading regimen over another for patients with ischemic heart disease or impaired left ventricular function, and these drugs
should be used cautiously or not at all in such patients.
dThe use of quinidine loading to achieve pharmacological conversion of atrial ﬁbrillation is controversial and safer methods are available with the alternative agents listed in the table. Quinidine should be used
with caution.
AF indicates atrial ﬁbrillation; BID, twice a day; GI, gastrointestinal; and IV, intravenous.
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with 100, 39% with 200, and 95% with 360 J, respectively),
resulting in fewer shocks and less cumulative energy when
360 J was delivered initially.262 These data indicate that
an initial shock of 100 J with monophasic waveform is
often too low for direct-current cardioversion of AF;
hence, an initial energy of 200 J or greater is recommended.
A similar recommendation to start with 200 J applies to
biphasic waveforms, particularly when cardioverting
patients with AF of long duration.263
When appropriate precautions are taken, cardioversion of
AF is safe in patients with implanted pacemaker or deﬁbril-
lator devices. Pacemaker generators and deﬁbrillators are
designed with circuits protected against sudden external
electrical discharges, but programmed data may be
altered by current surges. Electricity conducted along an
implanted electrode may cause endocardial injury and
lead to a temporary or permanent increase in stimulation
threshold resulting in loss of ventricular capture. To ensure
appropriate function, the implanted device should be inter-
rogated and, if necessary, reprogrammed before and after
cardioversion.
b. Risks and complications of direct-current cardioversion
of atrial ﬁbrillation
The risks of direct-current cardioversion are mainly related
to thromboembolism and arrhythmias. Thromboembolic
events have been reported in 1% to 7% of patients not
given prophylactic anticoagulation before cardioversion of
AF.264,265 Prophylactic antithrombotic therapy is discussed
in Section VIII.B.5.c, Pharmacological enhancement of
direct-current cardioversion.
Figure 8 Pharmacological management of patients with recurrent paroxysmal atrial ﬁbrillation (AF). *See Figure 9. AAD indicates antiarrhythmic drug.
Figure 7 Pharmacological management of patients with newly discovered atrial ﬁbrillation (AF). *See Figure 9. HF indicates heart failure.
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c. Pharmacological enhancement of direct-current
cardioversion
Although most recurrences of AF occur within the ﬁrst
month after direct-current cardioversion, research with
internal atrial cardioversion270 and postconversion studies
using transthoracic shocks271 have established several pat-
terns of AF recurrence (Figure 7). In some cases, direct-
current countershock fails to elicit even a single isolated
sinus or ectopic atrial beat, tantamount to a high atrial deﬁ-
brillation threshold. In others, AF recurs within a few
minutes after a period of sinus rhythm,272 and recurrence
after cardioversion is sometimes delayed for days or
weeks.271 Complete shock failure and immediate recurrence
occur in approximately 25% of patients undergoing direct-
current cardioversion of AF, and subacute recurrences
occur within 2 wk in almost an equal proportion.273
Restoration and maintenance of sinus rhythm are less
likely when AF has been present for more than 1 y than in
patients with AF of shorter duration. The variation in
immediate success rates for direct-current cardioversion
Figure 10 Pharmacological management of patients with recurrent persistent or permanent atrial ﬁbrillation (AF). *See Figure 9. Initiate drug therapy before
cardioversion to reduce the likelihood of early recurrence of AF. AAD indicates antiarrhythmic drug.
Figure 9 Antiarrhythmic drug therapy to maintain sinus rhythm in patients with recurrent paroxysmal or persistent atrial ﬁbrillation. Within each box, drugs are
listed alphabetically and not in order of suggested use. The vertical ﬂow indicates order of preference under each condition. The seriousness of heart disease
proceeds from left to right, and selection of therapy in patients with multiple conditions depends on the most serious condition present. See Section 8.3.3.3 in
the full-text guidelines for details. LVH indicates left ventricular hypertrophy.
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from 70% to 99% in the literature262,274–276 is partly
explained by differences in patient characteristics and the
waveform used but also depends on the deﬁnition of
success, because the interval at which the result is evalu-
ated ranges from moments to several days. In general, it
appears that sinus rhythm can be restored in a substantial
proportion of patients by direct-current cardioversion, but
the rate of relapse is high without concomitant anti-
arrhythmic drug therapy.
When given in conjunction with direct-current cardiover-
sion, the primary aims of antiarrhythmic medication therapy
are to increase the likelihood of success (e.g., by lowering
the cardioversion threshold) and to prevent recurrent AF.
Antiarrhythmic medications may be initiated out of hospital
or in hospital immediately prior to direct-current
cardioversion. (See Section 8.1.7 in the full-text guidelines,
Out-of-hospital initiation of antiarrhythmic drugs in
patients.) The risks of pharmacological treatment include
the possibility of paradoxically increasing the deﬁbrillation
threshold, as described with ﬂecainide,277 accelerating the
ventricular rate when class IA or IC drugs are given
without an AV nodal blocking agent,256,257,278,279 and indu-
cing ventricular arrhythmias (Table 17).
Patients with lone AF of relatively short duration are less
prone to early recurrence of AF than are those with heart
disease and longer AF duration, who therefore stand to
gain more from prophylactic administration of anti-
arrhythmic medication. Pretreatment with pharmacological
agents is most appropriate in patients who fail to respond to
direct-current cardioversion and in those who develop
immediate or subacute recurrence of AF. In patients with
late recurrence and those undergoing initial cardioversion
of persistent AF, pretreatment is optional. Antiarrhythmic
drug therapy is recommended in conjunction with a
second cardioversion attempt, particularly when early
relapse has occurred. Additional cardioversion, beyond a
second attempt, is of limited value and should be reserved
for carefully selected patients, but infrequently repeated
cardioversions may be acceptable in patients who are
highly symptomatic upon relapse to AF.
Available data suggest that starting pharmacological
therapy and establishing therapeutic plasma drug concen-
trations before direct-current cardioversion enhances
immediate success and suppresses early recurrences. After
cardioversion to sinus rhythm, patients receiving drugs
that prolong the QT interval should be monitored in the hos-
pital for 24 to 48 h to evaluate the effects of heart rate
slowing and allow for prompt intervention in the event tor-
sades de pointes develops (Table 18).
In randomized studies of direct-current cardioversion,
patients pretreated with ibutilide were more often con-
verted to sinus rhythm than untreated controls and those
in whom cardioversion initially failed could more often be
converted when the procedure was repeated after treat-
ment with ibutilide.280,281
d. Prevention of thromboembolism in patients with atrial
ﬁbrillation undergoing conversion
Randomized studies of antithrombotic therapy are lacking
for patients undergoing cardioversion of AF or atrial
Table 15 Typical doses of drugs used to maintain sinus rhythm in patients with atrial ﬁbrillationa
Drugb Daily dosage Potential adverse effects
Amiodaronec 100 to 400 mg Photosensitivity, pulmonary toxicity, polyneuropathy, GI upset, bradycardia, torsades de pointes
(rare), hepatic toxicity, thyroid dysfunction, eye complications
Disopyramide 400 to 750 mg Torsades de pointes, HF, glaucoma, urinary retention, dry mouth
Dofetilided 500 to 1000 mcg Torsades de pointes
Flecainide 200 to 300 mg Ventricular tachycardia, HF, conversion to atrial ﬂutter with rapid conduction through the AV node
Propafenone 450 to 900 mg Ventricular tachycardia, HF, conversion to atrial ﬂutter with rapid conduction through the AV node
Sotalold 160 to 320 mg Torsades de pointes, HF, bradycardia, exacerbation of chronic obstructive or bronchospastic lung
disease
aDrugs and doses given here have been determined by consensus on the basis of published studies.
bDrugs are listed alphabetically.
cA loading dose of 600 mg per day is usually given for one month or 1000 mg per day for 1 week.
dDose should be adjusted for renal function and QT-interval response during in-hospital initiation phase.
AF indicates atrial ﬁbrillation; AV, atrioventricular; GI, gastrointestinal; and HF, heart failure.
Table 14 Vaughan Williams classiﬁcation of antiarrhythmic
drugs
Type IA
Disopyramide
Procainamide
Quinidine
Type IB
Lidocaine
Mexiletine
Type IC
Flecainide
Propafenone
Type II
Beta blockers (e.g., propranolol)
Type III
Amiodarone
Bretylium
Dofetilide
Ibutilide
Sotalol
Type IV
Nondihydropyridine calcium channel antagonists (verapamil
and diltiazem)
Table includes compounds introduced after publication of the original
classiﬁcation.
Modiﬁed with permission from Vaughan Williams EM. A classiﬁcation of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin
Pharmacol 1984;24:129–47.196 & 1984 by Sage Publications Inc.
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ﬂutter, but in case-control series the risk of thromboembo-
lism was between 1% and 5%.265,282 The risk was near the
low end of this spectrum when anticoagulation (INR 2.0 to
3.0) was given for 3 to 4 wk before and after conver-
sion.62,269 It is common practice to administer anticoagulant
drugs when preparing patients with AF of more than 2-d dur-
ation for cardioversion. Manning et al.283 suggested that TEE
might be used to identify patients without LAA thrombus
who do not require anticoagulation, but a subsequent inves-
tigation284 and meta-analysis found this approach
unreliable.285
If most AF-associated strokes result from embolism of
stasis-induced thrombus from the LAA, then restoration
and maintenance of atrial contraction should logically
reduce thromboembolic risk. There is no evidence,
however, that cardioversion followed by prolonged mainten-
ance of sinus rhythm effectively reduces thromboembolism
in AF patients. Conversion of AF to sinus rhythm results in
transient mechanical dysfunction of the LA and LAA286
(‘stunning’), which can occur after spontaneous, pharmaco-
logical,287,288 or electrical288–290 conversion of AF or after
radiofrequency catheter ablation of atrial ﬂutter.91
Recovery of mechanical function may be delayed, depending
in part on the duration of AF before conversion.291–293 This
could explain why some patients without demonstrable LA
thrombus on TEE before cardioversion subsequently experi-
ence thromboembolic events.284 Presumably, thrombus
forms during the period of stunning and is expelled after
the return of mechanical function, explaining the clustering
of thromboembolic events during the ﬁrst 10 d after
cardioversion.84
Patients with AF or atrial ﬂutter in whom LAA thrombus is
identiﬁed by TEE are at high risk of thromboembolism and
should be anticoagulated for at least 3 wk prior to and 4
wk after pharmacological or direct-current cardioversion.
In a multicenter study, 1222 patients with either AF persist-
ing longer than 2 d or atrial ﬂutter and previous AF294 were
randomized to a TEE-guided or conventional strategy. In the
group undergoing TEE, cardioversion was postponed when
thrombus was identiﬁed, and warfarin was administered
for 3 wk before TEE was repeated to conﬁrm resolution of
thrombus. Anticoagulation with heparin was used brieﬂy
before cardioversion and with warfarin for 4 wk after cardi-
oversion. The other group received anticoagulation for 3 wk
before and 4 wk after cardioversion without intercurrent
TEE. Both approaches were associated with comparably
low risks of stroke (0.81% with the TEE approach and
0.50% with the conventional approach) after 8 wk, there
were no differences in the proportion of patients achieving
successful cardioversion, and the risk of major bleeding
did not differ signiﬁcantly. The clinical beneﬁt of the TEE-
guided approach was limited to saving time before
cardioversion.
Anticoagulation is recommended for 3 wk prior to and 4
wk after cardioversion for patients with AF of unknown dur-
ation or with AF for longer than 48 h. Although LA thrombus
and systemic embolism have been documented in patients
with AF of shorter duration, the need for anticoagulation
is less clear. When acute AF produces hemodynamic instabil-
ity in the form of angina pectoris, MI, shock, or pulmonary
edema, immediate cardioversion should not be delayed to
deliver therapeutic anticoagulation, but intravenous unfrac-
tionated heparin or subcutaneous injection of a
low-molecular-weight heparin should be initiated before
cardioversion by direct-current countershock or intravenous
antiarrhythmic medication.
Protection against late embolism may require continu-
ation of anticoagulation for a more extended period after
Table 16 Factors predisposing to drug-induced ventricular proarrhythmia
VW types IA and III agents VW type IC agents
Long QT interval (QTc greater than or equal to 460 ms) Wide QRS duration (more than 120 ms)
Long QT interval syndrome Concomitant VT
Structural heart disease, substantial LVH Structural heart disease
Depressed LV functiona Depressed LV functiona
Hypokalemia/hypomagnesemiaa
Female gender
Renal dysfunctiona
Bradycardiaa Rapid ventricular response ratea
1. (Drug-induced) sinus node disease or AV block 1. During exercise
2. (Drug-induced) conversion of AF to sinus rhythm 2. During rapid AV conduction
3. Ectopy producing short-long R-R sequences
Rapid dose increase Rapid dose increase
High dose (sotalol, dofetilide), drug accumulationa High dose, drug accumulationa
Addition of drugsa Addition of drugsa
1. Diuretics 1. Negative inotropic drugs
2. Other QT-prolonging antiarrhythmic drugs
3. Nonantiarrhythmic drugs listed in http://www.torsades.org/
Previous proarrhythmia
After initiation of drug
Excessive QT lengthening Excessive (more than 150%) QRS widening
aSome of these factors may develop later after initiation of drug treatment. See Section 8.3.3.3 in the full-text guidelines
for details. Vaughan Williams (VW) classiﬁcation of antiarrhythmic drugs from Vaughan Williams EM. A classiﬁcation of
antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol 1984;24:129–47.196
AF indicates atrial ﬁbrillation; AV, atrioventricular; LV, left ventricular; LVH, left ventricular hypertrophy; QTc, indicates corrected
QT interval; and VT, ventricular tachycardia.
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the procedure, and the duration of anticoagulation after
cardioversion depends both on the likelihood that AF will
recur in an individual patient with or without symptoms
and on the intrinsic risk of thromboembolism. Late events
are probably due to both the development of thrombus as
a consequence of atrial stunning and the delayed recovery
of atrial contraction after cardioversion. Stroke or systemic
embolism has been reported in patients with atrial ﬂutter
undergoing cardioversion,295–297 and anticoagulation should
be considered with either the conventional or TEE-guided
strategy. TEE-guided cardioversion of atrial ﬂutter has
been performed with a low rate of systemic embolism, par-
ticularly when patients are stratiﬁed for other risk factors on
the basis of clinical and/or TEE features.
6. Maintenance of sinus rhythm
a. Pharmacological therapy
Whether paroxysmal or persistent, AF is a chronic disorder,
and recurrence at some point is likely in most
patients.299–301 Many patients eventually need prophylactic
antiarrhythmic drug therapy to maintain sinus rhythm, sup-
press symptoms, improve exercise capacity and hemody-
namic function, and prevent tachycardia-induced
cardiomyopathy due to AF. Because factors that predispose
to recurrent AF (advanced age, HF, hypertension, LA enlar-
gement, and LV dysfunction) are risk factors for thromboem-
bolism, the risk of stroke may not be reduced by correction
of the rhythm disturbance. Trials in which rate versus
rhythm control strategies were compared in patients with
persistent and paroxysmal AF124,126,127,130,132 found no
reduction in death, disabling stroke, hospitalizations, new
arrhythmias, or thromboembolic complications in the
rhythm control group.
b. Predictors of recurrent atrial ﬁbrillation
Most patients with AF, except those with postoperative or
self-limited AF secondary to transient or acute illness, even-
tually experience recurrence. Risk factors for frequent
recurrence of paroxysmal AF (more than 1 episode per
month) include female gender and underlying heart
disease.302 In 1 study of patients with persistent AF, the
4-y arrhythmia-free survival rate was less than 10% after
single-shock direct-current cardioversion without prophy-
lactic drug therapy.300 Predictors of recurrences within
that interval included hypertension, age over 55 y, and AF
duration of longer than 3 mo. Serial cardioversions and
Table 18 Pharmacological treatment before cardioversion in patients with persistent AF: effects of various antiarrhythmic
drugs on immediate recurrence, outcome of transthoracic direct-current shock, or both
Efﬁcacy Enhance conversion
by DC shock and
prevent IRAFa
Recommendation
class
Level of
evidence
Suppress SRAF and maintenance
therapy class
Known Amiodarone IIa B All drugs in recommendation
class I (except ibutilide) plus
beta blockers
Flecainide
Ibutilide
Propafenone
Sotalol
Uncertain/unknown Beta-blockers IIb C Diltiazem
Diltiazem Dofetilide
Disopyramide Verapamil
Dofetilide
Procainamide
Verapamil
aDrugs are listed alphabetically within each class of recommendation.
All drugs (except beta blockers and amiodarone) should be initiated in the hospital.
AF indicates atrial ﬁbrillation; DC, direct-current; IRAF, immediate recurrence of atrial ﬁbrillation; and SRAF, subacute recurrence of atrial
ﬁbrillation.
Table 17 Types of proarrhythmia during treatment with various
antiarrhythmic drugs for AF or atrial ﬂutter according to the
Vaughan Williams classiﬁcation
A. Ventricular proarrhythmia
Torsades de pointes (VW types IA and III drugsa)
Sustained monomorphic ventricular tachycardia (usually VW
type IC drugs)
Sustained polymorphic ventricular tachycardia/VF without
long QT (VW types IA, IC, and III drugs)
B. Atrial proarrhythmia
Provocation of recurrence (probably VW types IA, IC, and III
drugs)
Conversion of AF to ﬂutter (usually VW type IC drugs)
Increase of deﬁbrillation threshold (a potential problem with
VW type IC drugs)
C. Abnormalities of conduction or impulse formation
Acceleration of ventricular rate during AF (VW types IA and IC
drugs)
Accelerated conduction over accessory pathway (digoxin,
intravenous verapamil, or diltiazemb)
Sinus node dysfunction, atrioventricular block (almost all
drugs)
aThis complication is rare with amiodarone.
bAlthough the potential for beta blockers to potentiate conduction
across the accessory pathway is controversial, caution should also be
exercised for the use of these agents in patients with atrial ﬁbrillation
(AF) associated with preexcitation.
Vaughan Williams (VW) classiﬁcation of antiarrhythmic drugs from
Vaughan Williams EM. A classiﬁcation of antiarrhythmic actions reassessed
after a decade of new drugs. J Clin Pharmacol 1984;24:129–47.196
VF indicates ventricular ﬁbrillation.
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prophylactic drug therapy resulted in freedom from recur-
rent AF in approximately 30% of patients,300 and with this
approach predictors of recurrence included age over 70 y,
AF duration beyond 3 mo, and HF.300 Other risk factors for
recurrent AF include LA enlargement and rheumatic heart
disease.
Various benign arrhythmias, especially ventricular and
supraventricular premature beats, bradycardia, and short
periods of sinus arrest, may arise after cardioversion and
commonly subside spontaneously.266 More dangerous
arrhythmias, such as ventricular tachycardia and ﬁbrillation,
may arise in the face of hypokalemia, digitalis intoxication,
or improper synchronization.267,268 Serum potassium levels
should be in the normal range for safe, effective cardiover-
sion. Cardioversion is contraindicated in cases of digitalis
toxicity because resulting ventricular tachyarrhythmia may
be difﬁcult to terminate.
In patients with long-standing AF, cardioversion commonly
unmasks underlying sinus node dysfunction. A slow ventricu-
lar response to AF in the absence of drugs that slow conduc-
tion across the AV node may indicate an intrinsic conduction
defect. The patient should be evaluated before cardiover-
sion with this in mind so a transvenous or transcutaneous
pacemaker can be used prophylactically.269
c. General approach to antiarrhythmic drug therapy
Before administering any antiarrhythmic agent, reversible
precipitants of AF should be identiﬁed and corrected. Most
are related to coronary or valvular heart disease, hyperten-
sion, or HF. Patients who develop AF in association with
alcohol intake should abstain from alcohol consumption.
Indeﬁnite antiarrhythmic treatment is seldom prescribed
after a ﬁrst episode, although a period of several weeks
may help stabilize sinus rhythm after cardioversion.
Similarly, patients experiencing breakthrough arrhythmias
may not require a change in antiarrhythmic drug therapy
when recurrences are infrequent and mild. Beta-adrenergic
antagonist medication may be effective in patients who
develop AF only during exercise, but a single, speciﬁc incit-
ing cause rarely accounts for all episodes of AF, and the
majority of patients do not sustain sinus rhythm without
antiarrhythmic therapy. Selection of an appropriate agent
is based ﬁrst on safety, tailored to whatever underlying
heart disease may be present, considering the number and
pattern of prior episodes of AF.303
In patients with lone AF, a beta blocker may be tried ﬁrst,
but ﬂecainide, propafenone, and sotalol are particularly
effective. Amiodarone and dofetilide are recommended as
alternative therapies. Quinidine, procainamide, and disopyr-
amide are not favored unless amiodarone fails or is contra-
indicated. For patients with vagally induced AF, however,
the anticholinergic activity of long-acting disopyramide
makes it a relatively attractive theoretical choice. In that
situation, ﬂecainide and amiodarone represent secondary
and tertiary treatment options, respectively, whereas pro-
pafenone is not recommended because its (weak) intrinsic
beta-blocking activity may aggravate vagally mediated par-
oxysmal AF. In patients with adrenergically mediated AF,
beta blockers represent ﬁrst-line treatment, followed by
sotalol and amiodarone. In patients with adrenergically
mediated lone AF, amiodarone represents a less appealing
selection. Vagally induced AF can occur by itself, but more
typically it is part of the overall patient proﬁle. In patients
with nocturnal AF, the possibility of sleep apnea should be
considered.
When treatment with a single antiarrhythmic drug fails,
combinations may be tried. Useful combinations include a
beta blocker, sotalol, or amiodarone with a class IC agent.
The combination of a calcium channel blocker, such as diltia-
zem, with a class IC agent, such as ﬂecainide or propafe-
none, is advantageous in some patients. A drug that is
initially safe may become proarrhythmic if coronary
disease or HF develops or if the patient begins other medi-
cation that exerts a proarrhythmic interaction. Thus, the
patient should be alerted to the potential signiﬁcance of
such symptoms as syncope, angina, or dyspnea and warned
about the use of noncardiac drugs that might prolong the
QT interval.
The optimum method for monitoring antiarrhythmic drug
treatment varies with the agent involved as well as with
patient factors. Prospectively acquired data on upper
limits of drug-induced prolongation of QRS duration or QT
interval are not available. With class IC drugs, prolongation
of the QRS interval should not exceed 50%. Exercise testing
may help detect QRS widening that occurs only at rapid
heart rates (use-dependent conduction slowing). For class
IA or class III drugs, with the possible exception of amiodar-
one, the corrected QT interval in sinus rhythm should be
kept below 520 ms. During follow-up, plasma potassium
and magnesium levels and renal function should be
checked periodically because renal insufﬁciency leads to
drug accumulation and predisposes to proarrhythmia. In
individual patients, serial noninvasive assessment of LV func-
tion is indicated, especially when clinical HF develops during
treatment of AF.
d. Selection of antiarrhythmic agents in patients with
cardiac diseases
Pharmacological management algorithms to maintain sinus
rhythm in patients with AF (see Figures 7–10) and appli-
cations in speciﬁc cardiac disease states are based on avail-
able evidence and extrapolated from experience with these
agents in other situations.
Heart failure. Patients with HF are particularly prone to the
ventricular proarrhythmic effects of antiarrhythmic drugs
because of myocardial vulnerability and electrolyte imbal-
ance. Randomized trials have demonstrated the safety of
amiodarone and dofetilide (given separately) in patients
with HF,200,304 and these are the recommended drugs for
maintenance of sinus rhythm in patients with AF in the pre-
sence of HF (Figure 9). Patients with LV dysfunction and per-
sistent AF should be treated with beta blockers and ACE
inhibitors and/or angiotensin II receptor antagonists,
because these agents help control the heart rate, improve
ventricular function, and prolong survival.305–308
Coronary artery disease. In stable patients with CAD, beta
blockers may be considered ﬁrst, although their use is sup-
ported by only 2 studies309,310 and data on efﬁcacy for main-
tenance of sinus rhythm in patients with persistent AF after
cardioversion are not convincing.310 Sotalol has substantial
beta-blocking activity and may be the preferred initial anti-
arrhythmic agent in patients with AF who have ischemic
heart disease because it is associated with less long-term
toxicity than amiodarone. Amiodarone increases the risk
of bradyarrhythmia requiring permanent pacemaker
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implantation in elderly patients with AF who have previously
sustained MI311 but may be preferred over sotalol in patients
with HF.312,313 Neither ﬂecainide nor propafenone is rec-
ommended in these situations, but quinidine, procainamide,
and disopyramide may be considered as third-line choices in
patients with coronary disease. The DIAMOND-MI (Danish
Investigations of Arrhythmias and Mortality on Dofetilide in
Myocardial Infarction) trial314 involved selected post-MI
patients in whom the antiarrhythmic beneﬁt of dofetilide
balanced the risk of proarrhythmic toxicity, making this a
second-line antiarrhythmic agent. In patients with coronary
disease who have not developed MI or HF, however, it is
uncertain whether the beneﬁt of dofetilide outweighs risk,
and more experience is needed before this drug can be rec-
ommended for such patients (Figure 9).
Hypertensive heart disease. Hypertension is the most preva-
lent and potentially modiﬁable independent risk factor for
the development of AF and its complications, including
thromboembolism.315,316 Blood pressure control may
become an opportune strategy for the prevention of AF.
Patients with LVH may face an increased risk of torsades
de pointes related to early ventricular afterdepolariza-
tions.303,317 Thus, class IC agents and amiodarone are pre-
ferred over type IA and type III antiarrhythmic agents as
ﬁrst-line therapy. In the absence of ischemia or LVH, both
propafenone and ﬂecainide are reasonable choices.
Proarrhythmia with 1 agent does not predict this response
to another, and patients with LVH who develop torsades de
pointes during treatment with a class III agent may tolerate
a class IC agent. Amiodarone prolongs the QT interval but
carries a very low risk of ventricular proarrhythmia. Its
extracardiac toxicity relegates it to second-line therapy in
these individuals, but it becomes a ﬁrst-line agent in the
face of substantial LVH. When amiodarone and sotalol
either fail or are inappropriate, disopyramide, quinidine,
or procainamide represents a reasonable alternative.
Beta blockers may be the ﬁrst line of treatment to maintain
sinus rhythm in patients with MI, HF, and hypertension.
Compared to patients with lone AF, those with hypertension
are more likely to maintain sinus rhythm after cardioversion
of persistent AF when treated with a beta blocker.318 Drugs
modulating the RAAS reduce structural cardiac changes,319
and ACE inhibition was associated with a lower incidence of
AF compared with calcium channel blockade in patients
with hypertension during 4.5 y of follow-up in a retrospec-
tive, longitudinal cohort study from a database of 8 million
patients in a managed care setting.320 In patients at increased
risk of cardiovascular events, therapy with either the ACE
inhibitor ramipril321–323 or angiotensin receptor antagonist
losartan324,325 lowered the risk of stroke. A similar beneﬁt
has been reported with perindopril in a subset of patients
with AF treated for prevention of recurrent stroke.326 New-
onset AF and stroke were signiﬁcantly reduced by losartan
as compared to atenolol in hypertensive patients with ECG-
documented LVH, despite a similar reduction of blood
pressure.16 The beneﬁt of losartan was greater in patients
with AF than in those with sinus rhythm for the primary com-
posite endpoint (cardiovascular mortality, stroke, and MI) and
for cardiovascular mortality alone.327 Presumably, the ben-
eﬁcial effects of beta blockers and drugs modulating the
RAAS are at least partly related to lower blood pressure.
7. Nonpharmacological therapy for atrial ﬁbrillation
The inconsistent efﬁcacy and potential toxicity of anti-
arrhythmic drug therapies have stimulated exploration of a
wide spectrum of alternative nonpharmacological therapies
for the prevention and control of AF.
a. Surgical ablation
A decade of research in the 1980s demonstrated the critical
elements necessary to cure AF surgically, including tech-
niques that entirely eliminate macroreentrant circuits in
the atria while preserving sinus node and atrial transport
functions. The surgical approach was based on the hypoth-
esis that reentry is the predominant mechanism responsible
for the development and maintenance of AF,328 leading to
the concept that atrial incisions at critical locations would
create barriers to conduction and prevent sustained AF.
The procedure developed to accomplish these goals was
based on the concept of a geographical maze, accounting
for the term ‘maze’ procedure used to describe this type
of cardiac operation.329
Since its introduction, the procedure has gone through 3
iterations (maze I, II, and III) using cut-and-sew techniques
that ensure transmural lesions to isolate the PV, connect
these dividing lines to the mitral valve annulus, and create
electrical barriers in the RA that prevent macroentrant
rhythms—atrial ﬂutter or AF—from becoming sustained.330
Success rates of around 95% over 15 y of follow-up have
been reported in patients undergoing mitral valve
surgery.331 Other studies suggest success rates around
70%.332 Atrial transport function is maintained and, when
combined with amputation or obliteration of the LAA, post-
operative thromboembolic events are substantially reduced.
Risks include death (less than 1% when performed as an iso-
lated procedure), the need for permanent pacing (with right-
sided lesions), recurrent bleeding requiring re-operation,
impaired atrial transport function, delayed atrial arrhythmias
(especially atrial ﬂutter), and atrioesophageal ﬁstula.
Despite its high success rate, the maze operation has not
been widely adopted other than for patients undergoing
cardiac surgery because of the need for cardiopulmonary
bypass. A wide variety of less invasive modiﬁcations are
under investigation, including thoracoscopic and catheter-
based epicardial techniques.332 If the efﬁcacy of these adap-
tations approaches that of the endocardial maze procedure
and they can be performed safely, they may become accep-
table alternatives for a larger proportion of patients with AF.
b. Catheter ablation
Early radiofrequency catheter ablation techniques emulated
the surgical maze procedure by introducing linear scars in
the atrial endocardium.333 While the success rate was
approximately 40% to 50%, a relatively high complication
rate diminished enthusiasm for this approach.38 The obser-
vation that potentials arising in or near the ostia of the PV
often provoked AF and demonstration that elimination of
these foci abolished AF escalated enthusiasm for catheter-
based ablation.38 Initially, areas of automaticity within the
PV were targeted, and in a series of 45 patients with parox-
ysmal AF, 62% became free of symptomatic AF over a mean
follow-up of 8 mo, but 70% required multiple procedures.38
In another study, the success rate was 86% over a 6-mo
follow-up.334 Subsequent research has demonstrated that
potentials may arise in multiple regions of the RA and LA,
including the LA posterior wall, superior vena cava, vein of
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Marshall, crista terminalis, interatrial septum, and coronary
sinus,335 and modiﬁcation of the procedures has incorpor-
ated linear LA ablation, mitral isthmus ablation, or both
for selected patients.336
The technique of ablation has continued to evolve from
early attempts to target individual ectopic foci within the
PV to circumferential electrical isolation of the entire PV
musculature. In a series of 70 patients, 73% were free
from AF following PV isolation without antiarrhythmic medi-
cations during a mean follow-up of 4 mo, but 29 patients
required a second procedure to reach this goal. However,
post-ablation AF may occur transiently in the ﬁrst 2 mo.337
Advances involving isolation of the PV at the antrum using
a circular mapping catheter, guided by intracardiac echocar-
diography, have reportedly yielded approximately 80%
freedom of recurrent AF or atrial ﬂutter after the ﬁrst
2 mo in patients with paroxysmal AF,338 but success rates
were lower in patients with cardiac dysfunction.339 Still
another approach340,341 uses a nonﬂuoroscopic guidance
system and radiofrequency energy delivered circumferen-
tially outside the ostia of the PV. In a series of 26 patients,
85% were free of recurrent AF during a mean follow-up of
9 mo, including 62% taking no antiarrhythmic medications.
The accumulated experience involves nearly 4000
patients,341 with approximately 90% success in cases of par-
oxysmal AF and 80% in cases of persistent AF.339,342,343
Another anatomic approach to radiofrequency catheter
ablation targets complex fractionated electrograms344 with
91% efﬁcacy reported at 1 y. Restoration of sinus rhythm
after catheter ablation for AF signiﬁcantly improved LV func-
tion, exercise capacity, symptoms, and quality of life
(usually within the ﬁrst 3 to 6 mo), even in the presence
of concurrent heart disease and when ventricular rate
control was adequate before ablation.345 While that study
lacked a control group of patients with HF, in another
study catheter ablation of AF was associated with reduced
mortality and morbidity due to HF and thromboembolism.346
In selected patients, radiofrequency catheter ablation of
the AV node and pacemaker insertion decreased symptoms
of AF and improved quality-of-life scores compared with
medication therapy.140–142,347–349 A meta-analysis of 10
studies of patients with AF143 found improvement in both
symptoms and quality-of-life scores after ablation and
pacing. Although these studies involved selected patients
who remained in AF, the consistent improvement suggests
that quality of life was impaired before intervention.
Despite these advances, the long-term efﬁcacy of cath-
eter ablation to prevent recurrent AF requires further
study. Available data demonstrate 1 or more y free from
recurrent AF in most (albeit carefully selected)
patients.350–352 It is important to bear in mind, however,
that AF can recur without symptoms and be unrecognized
by the patient or the physician. Therefore, it remains uncer-
tain whether apparent cures represent elimination of AF or
transformation into an asymptomatic form of paroxysmal AF.
The distinction has important implications for the duration
of anticoagulation therapy in patients with risk factors for
stroke associated with AF. In addition, little information is
available about the late success of ablation in patients
with HF and other advanced structural heart disease, who
may be less likely to enjoy freedom from AF recurrence.
Complications of catheter ablation include the adverse
events associated with any cardiac catheterization procedure
in addition to those speciﬁc to ablation of AF. Major compli-
cations have been reported in about 6% of procedures and
include PV stenosis, thromboembolism, atrioesophageal
ﬁstula, and LA ﬂutter.343 The initial ablation approach
targeting PV ectopy was associated with an unacceptably
high rate of PV stenosis,334,353 but the incidence has dramati-
cally decreased as a result of changes in technique. Current
approaches avoid delivering radiofrequency energy within
the PV and instead target areas outside the veins to isolate
the ostia from the remainder of the LA conducting tissue.
Use of intracardiac echocardiographically detected micro-
bubble formation to titrate radiofrequency energy has also
been reported to reduce the incidence of PV stenosis.338
Embolic stroke is among the most serious complications of
catheter-based ablation procedures in patients with AF. The
incidence varies from 0% to 5%. A higher intensity of anti-
coagulation reduces the risk of thrombus formation during
ablation.354 Based on limited data from dose-comparison
studies, it seems likely that more aggressive anticoagulation
may reduce the incidence of thromboembolism associated
with catheter-based ablation of AF.
Atrioesophageal ﬁstula has been reported with both the
circumferential Pappone approach355,356 and the
Haissaguerre PV ablation techniques356 but is relatively
rare. This complication may be more likely to occur when
extensive ablative lesions are applied to the posterior LA
wall, increasing the risk of atrial perforation. The typical
manifestations include sudden neurological symptoms or
endocarditis, and the outcome in most cases is, unfortu-
nately, fatal. Depending on the ablation approach, LA
ﬂutter may develop during treatment of AF,357 and this is
amenable to further ablation.358
Future directions in catheter-based ablation therapy for
atrial ﬁbrillation. Catheter-directed ablation of AF rep-
resents a substantial achievement that promises better
therapy for a large number of patients presently resistant
to pharmacological or electrical conversion to sinus rhythm.
The limited available studies suggest that catheter-based
ablation offers beneﬁt to selected patients with AF, but
these studies do not provide convincing evidence of
optimum catheter positioning or absolute rates of treatment
success. Identiﬁcation of patients who might beneﬁt from
ablation must take into account both potential beneﬁts and
short- and long-term risks. Rates of success and complications
vary, sometimes considerably, from one study to another
because of patient factors, patterns of AF, criteria for deﬁ-
nition of success, duration of follow-up, and technical
aspects. Registries of consecutive case series should incorpor-
ate clear and prospectively deﬁned outcome variables.
Double-blind studies are almost impossible to perform, yet
there is a need for randomized trials in which evaluation of
outcomes is blinded as to treatment modality. A comprehen-
sive evaluation of the favorable and adverse effects of various
ablation techniques should include measures of quality of life
and recurrence rates compared with pharmacological strat-
egies for rhythm control and, when this is not successful,
with such techniques of rate control as AV node ablation
and pacing. Generation of these comparative data over rela-
tively long periods of observation would address the array of
invasive and conservative management approaches available
for management of patients with AF and provide a valuable
foundation for future practice guidelines.
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c. Suppression of atrial ﬁbrillation through pacing
Several studies have examined the role of atrial pacing,
either in the RA alone or in more than 1 atrial location, to
prevent recurrent paroxysmal AF. In patients with sympto-
matic bradycardia, the risk of AF is lower with atrial than
with ventricular pacing.359 In patients with sinus node
dysfunction and normal AV conduction, data from several
randomized trials support atrial or dual-chamber rather
than ventricular pacing for prevention of AF.360–363 The
mechanisms by which atrial pacing prevents AF in patients
with sinus node dysfunction include prevention of
bradycardia-induced dispersion of repolarization and sup-
pression of atrial premature beats. Atrial or dual-chamber
pacing also maintains AV synchrony, preventing retrograde
ventriculoatrial conduction, which can cause valvular regur-
gitation and stretch-induced changes in atrial electrophysi-
ology. When ventricular pacing with dual-chamber devices
is unavoidable because of concomitant disease of the AV
conduction system, the evidence is less clear that atrial-
based pacing is superior. Although atrial-based pacing is
associated with a lower risk of AF and stroke than
ventricular-based pacing in patients requiring pacemakers
for bradyarrhythmias, the value of pacing as a primary
therapy for prevention of recurrent AF has not been proven.
d. Internal atrial deﬁbrillators
There has been an interest in internal cardioversion of AF for
the past 10 y.135 Intense basic and clinical research to ﬁnd
tolerable shock waveforms led to evaluation of an implanta-
ble device capable of both atrial sensing and cardioversion
and ventricular sensing and pacing in 290 patients with
mean LV ejection fraction greater than 50% who had not
responded satisfactorily to therapy with 4 antiarrhythmic
drugs.135 The rate of conversion to sinus rhythm was 93%.
As spontaneous episodes were treated quickly, the interval
between episodes of AF lengthened. Several available
devices combining both atrial cardioversion and ventricular
deﬁbrillation capabilities with dual-chamber sensing and
pacing have been designed to treat both atrial and ventricu-
lar arrhythmias by pacing before delivering low- or high-
energy shocks.
An important limitation of atrial deﬁbrillators, unrelated
to efﬁcacy, is that most patients ﬁnd discharge energies
over 1 J uncomfortable. Candidates for atrial cardioverters
with infrequent episodes of poorly tolerated AF are typically
also candidates for catheter ablation. As a result, implanted
devices have limited utility, except for patients with LV dys-
function who are candidates for implantable ventricular
deﬁbrillators.
C. Primary prevention
Although measures aimed at the primary prevention of AF
have not been widely investigated, it has been suggested
that atrial or AV synchronous pacing may reduce the inci-
dence of subsequent AF in patients with bradycardia
compared with ventricular pacing.359,360 On the other
hand, studies in patients with intermittent atrial tachyar-
rhythmias failed to illustrate a general beneﬁt of atrial
pacing.360,365,366 Another potential avenue for primary pre-
vention has been suggested following secondary analysis of
placebo-controlled trials of treatment with ACE inhibi-
tors.56,367 In the LIFE (Losartan Intervention For End Point
Reduction in Hypertension)16 and CHARM (Candesartan in
Heart Failure Assessment of Reduction in Mortality and
Morbidity)368 trials, the angiotensin receptor antagonists
losartan and candesartan reduced the incidence of AF in
hypertensive patients with LVH16 and symptomatic HF,21,368
respectively. These results, together with their favorable
safety proﬁle compared with antiarrhythmic agents,
suggest a role for ACE inhibitor or angiotensin receptor
antagonists for primary prevention of initial or recurrent
episodes of AF associated with hypertension, MI, HF, or dia-
betes mellitus. An overview of 11 clinical trials involving
more than 56 000 patients with different underlying cardio-
vascular diseases suggests that ACE inhibitors or angiotensin
receptor blockers may reduce the occurrence and recur-
rence of AF.55
Yet inadequately explored, the use of statins has also
been suggested to protect against AF,369,370 and dietary
lipid components may inﬂuence the propensity of patients
to develop AF.371 In 449 patients with CAD followed for 5 y,
statin therapy reduced the incidence of AF—an effect not
observed with other lipid-lowering drugs.369 Insufﬁcient
data are available at this time to permit recommendations
for primary prevention of AF in populations at risk using
dietary interventions, pharmacological interventions, or
pacing or other devices.
IX. Proposed management strategies
A. Overview of algorithms for management of
patients with atrial ﬁbrillation
Management of patients with AF requires knowledge of its
pattern of presentation (paroxysmal, persistent, or perma-
nent), underlying conditions, and decisions about restor-
ation and maintenance of sinus rhythm, control of the
ventricular rate, and antithrombotic therapy. These issues
are addressed in the various management algorithms for
each presentation of AF (see Figures 7–10).
1. Newly discovered atrial ﬁbrillation
It is not always clear whether the initial presentation of AF is
actually the ﬁrst episode, particularly in patients with
minimal or no symptoms related to the arrhythmia. In
patients who have self-limited episodes of AF, anti-
arrhythmic drugs are usually unnecessary to prevent recur-
rence unless AF is associated with severe symptoms
related to hypotension, myocardial ischemia, or HF.
Regarding anticoagulation, the results of the AFFIRM
study132 indicate that patients with AF who are at high risk
for stroke on the basis of identiﬁed risk factors generally
beneﬁt from anticoagulation even after sinus rhythm has
been restored. Therefore, unless there is a clear reversible
precipitating factor for AF, such as hyperthyroidism that
has been corrected, the diagnosis of AF in a patient with
risk factors for thromboembolism should prompt long-term
anticoagulation.
When AF persists, one option is to accept progression to
permanent AF, with attention to antithrombotic therapy
and control of the ventricular rate. Although it may seem
reasonable to make at least one attempt to restore sinus
rhythm, the AFFIRM study showed no difference in survival
or quality of life with rate control compared to a rhythm
control strategies.132 Other trials that addressed this issue
reached similar conclusions.124,126,127,130 Hence, the
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decision to attempt restoration of sinus rhythm should be
based on the severity of arrhythmia-related symptoms and
the potential risk of antiarrhythmic drugs. If the decision
is made to attempt to restore and maintain sinus rhythm,
then anticoagulation and rate control are important before
cardioversion. Although long-term antiarrhythmic therapy
may not be needed to prevent recurrent AF after cardiover-
sion, short-term therapy may be beneﬁcial. In patients
with AF that has been present for longer than 3 mo, early
recurrence is common after cardioversion. In such cases,
antiarrhythmic medication may be initiated before cardio-
version (after adequate anticoagulation) to reduce the like-
lihood of recurrence, and the duration of drug therapy
would be brief (e.g., 1 mo).
2. Recurrent paroxysmal atrial ﬁbrillation
In patients who experience brief or minimally symptomatic
recurrences of paroxysmal AF, it is reasonable to avoid
antiarrhythmic drugs, but troublesome symptoms generally
call for suppressive antiarrhythmic therapy. Rate control
and prevention of thromboembolism are appropriate in
both situations. In a given patient, several antiarrhythmic
drugs may be effective and the initial selection is based
mainly on safety and tolerability (Figure 9). For individuals
with no or minimal heart disease, ﬂecainide, propafenone,
or sotalol is recommended as initial antiarrhythmic
therapy because they are generally well tolerated and
carry relatively little risk of toxicity. For patients with recur-
rent episodes of symptomatic AF who tolerate these agents,
an as-needed, pill-in-the-pocket approach may reduce the
risk of toxicity compared with sustained therapy. When
these drugs prove ineffective or are associated with side
effects, the second- or third-line choices include amiodar-
one, dofetilide, disopyramide, procainamide, or quinidine,
all of which carry greater potential for adverse reactions.
As an alternative to treatment with amiodarone or dofeti-
lide when ﬁrst-line antiarrhythmic drugs fail or are not
tolerated, PV isolation or LA substrate modiﬁcation may be
considered. When a consistent initiating scenario suggests
vagally mediated AF, drugs such as disopyramide or ﬂecai-
nide are appropriate initial agents, and a beta blocker or
sotalol is suggested for patients with adrenergically
induced AF. In particularly symptomatic patients, nonphar-
macological options such as LA ablation may be considered
when antiarrhythmic drug treatment alone fails to control
the arrhythmia.
Many patients with organic heart disease can be broadly
categorized into those with HF, CAD, or hypertension.
Other types of heart disease can be associated with AF,
and the clinician must determine which category best
describes the individual patient. For patients with HF,
safety data support the selection of amiodarone or dofeti-
lide to maintain sinus rhythm. Patients with CAD often
require beta-blocker medication, and sotalol, a drug with
both beta-blocking activity and primary antiarrhythmic
efﬁcacy, is considered ﬁrst, unless the patient has HF.
Amiodarone and dofetilide are considered secondary
agents, and the clinician should consider disopyramide,
procainamide, or quinidine on an individual basis.
The selection of antiarrhythmic drugs for patients with a
history of hypertension is confounded by the dearth of pro-
spective, controlled trials comparing the safety and efﬁcacy
of drug therapy for AF. In patients with hypertension
without LVH, drugs such as ﬂecainide and propafenone,
which do not prolong repolarization or the QT interval,
may offer a safety advantage and are recommended ﬁrst.
If these agents either prove ineffective or produce side
effects, then amiodarone, dofetilide, or sotalol represents
an appropriate secondary choice. Disopyramide, procaina-
mide, and quinidine are considered third-line agents in
this situation. Hypertrophied myocardium may be prone
to proarrhythmic toxicity and torsades de pointes ventricu-
lar tachycardia. Amiodarone is suggested as ﬁrst-line
therapy in patients with LVH because of its relative safety
compared with several other agents. Because neither ECG
nor echocardiography reliably detects LVH as deﬁned by
measurement of myocardial mass, clinicians may face a
conundrum.
The scarcity of data from randomized trials of anti-
arrhythmic medications for treatment of patients with AF
applies generally to all patient groups. Accordingly, the
drug-selection algorithms presented here have been devel-
oped by consensus and are subject to revision as additional
evidence emerges.
3. Recurrent persistent atrial ﬁbrillation
Patients with minimal or no symptoms referable to AF who
have undergone at least one attempt to restore sinus
rhythm may remain in AF after recurrence, with therapy
for rate control and prevention of thromboembolism as
needed. Alternatively, those with symptoms favoring sinus
rhythm should be treated with an antiarrhythmic agent (in
addition to medications for rate control and anticoagula-
tion) before cardioversion. The selection of an anti-
arrhythmic drug should be based on the same algorithm
used for patients with recurrent paroxysmal AF. If patients
remain symptomatic with heart rate control and anti-
arrhythmic medication is either not tolerated or ineffective,
then nonpharmacological therapies may be considered.
These include LA ablation, the maze operation, or AV
nodal ablation and pacing.
4. Permanent atrial ﬁbrillation
Permanent AF is the designation given to cases in which
sinus rhythm cannot be sustained after cardioversion of
AF or when the patient and physician have decided to
allow AF to continue without further efforts to restore
sinus rhythm. It is important to maintain control of the
ventricular rate and to use antithrombotic therapy, as out-
lined elsewhere in this document, for all patients in this
category.
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Appendix III Abbreviations
ACE angiotensin-converting enzyme
ACT activated clotting time
ACTIVE-W Atrial Fibrillation Clopidogrel Trial with Irbesartan
for Prevention of Vascular Events
ADONIS American-Australian Trial with Dronedarone in
Atrial Fibrillation or Flutter Patients for
Maintenance of Sinus Rhythm
AF atrial ﬁbrillation
AFASAK Copenhagen Atrial Fibrillation, Aspirin,
Anticoagulation
AF-CHF Atrial Fibrillation and Congestive Heart Failure
AFFIRM Atrial Fibrillation Follow-up Investigation of
Rhythm Management
AFI Atrial Fibrillation Investigators
ALFA Etude en Activite´ Libe´rale sur la Fibrillation
Auriculaire
ANP atrial naturetic peptide
APT Ablate and Pace Trial
ARCH Amiodarone Reduction in Coronary Heart
ATRIA Anticoagulation and Risk Factors in Atrial
Fibrillation
AV atrioventricular
BAATAF Boston Area Anticoagulation Trial for Atrial
Fibrillation
BNP B-type natriuretic peptide
CABG coronary artery bypass
CAD coronary artery disease
CAFA Canadian Atrial Fibrillation Anticoagulation
CAPRICORN Carvedilol Post-Infarct Survival Control in Left
Ventricular Dysfunction trial
CHADS2 Cardiac Failure, Hypertension, Age, Diabetes,
Stroke [Doubled]
CHAMP Combined Hemotherapy and Mortality Prevention
Study
CHARM Candesartan in Heart failure, Assessment of
Reduction in Mortality and morbidity
CHF-STAT Survival Trial of Antiarrhythmic Therapy in
Congestive Heart Failure
CI conﬁdence interval
CIBIS Cardiac Insufﬁciency Bisoprolol Study
COMET Carvedilol Or Metoprolol European Trial
CONSENSUS Co-operative North Scandinavian Enalapril
Survival Study
COPERNICUS Carvedilol Prospective Randomized Cumulative
Survival
COPD Chronic obstructive pulmonary disorder
CRP C-reactive protein
CTGF connective tissue growth factor
CVF-1 type 1 collagen volume fraction
DIAMOND Danish Investigations of Arrhythmias and Mortality
on Dofetilide
DIAMOND-MI Danish Investigations of Arrhythmia and Mortality
on Dofetilide-Myocardial Infarction
EAFT European Atrial Fibrillation Trial
ECG electrocardiogram
ELAT Embolism in the Left Atrial Thrombi
EMERALD European and Australian Multicenter Evaluative
Research on Atrial Fibrillation Dofetilide study
EP electrophysiological
ERK-2-mRNA extracellular signal-regulated kinase
messenger-RNA
ERP effective refractory period
ESPS II European Stroke Prevention Study II
EURIDIS European Trial in Atrial Fibrillation or Flutter
Patients Receiving Dronedarone for
Maintenance of Sinus Rhythm
FFAACS The French Fluindione-Aspirin Combination in
High Risk Patients With AF
GESICA Grupo Estudio de la Sobrevida en la Insufﬁcienca
Cardiaca en Argentina (V)
GUSTO-1 Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary
Arteries
HCM hypertrophic cardiomyopathy
HF heart failure
HOT CAFE´ How to Treat Chronic Atrial Fibrillation
HRV heart rate variability
IMP-2 atrial insulin-like growth factor-II mRNA-binding
protein 2
INR international normalized ratio
IRAF immediate recurrence of atrial ﬁbrillation
IVC inferior vena cava
LA left atrium
LAA LA appendage
LASAF Low-dose Aspirin, Stroke, Atrial Fibrillation
LIFE Losartan Intervention For End Point Reduction in
Hypertension study
LMWH low-molecular-weight heparin
LV left ventricle
MERIT-HF Metropolol CR/XL Randomized Intervention Trial
in Congestive Heart Failure
MI myocardial infarction
MMP-2 matrix metalloproteinase 2
NASPEAF National Study for Prevention of Embolism in Atrial
Fibrillation
PAFAC Prevention of atrial ﬁbrillation after cardioversion
PAPABEAR Prevention of Arrhythmias that Begin Early after
Revascularization, Valve Replacement,
or Repair
PATAF Prevention of Arterial Thromboembolism in Atrial
Fibrillation
PAVE Post AV Node Ablation Evaluation
PIAF Pharmacological Intervention in Atrial Fibrillation
PV pulmonary veins
RA right atrium
RAAS renin-angiotensin-aldosterone system
RACE Rate Control vs. Electrical cardioversion for
persistent atrial ﬁbrillation
RV right ventricular
SAFE-T Sotalol Amiodarone Atrial Fibrillation
Efﬁcacy Trial
SAFIRE-D Symptomatic Atrial Fibrillation Investigative
Research on Dofetilide
SEC spontaneous echo contrast
SIFA Studio Italiano Fibrillazione Atriale
SOLVD Studies of Left Ventricular Dysfunction
SOPAT Suppression of paroxysmal atrial tachyarrhythmias
SPAF Stroke Prevention in Atrial Fibrillation
SPINAF Stroke Prevention inNonrheumatic Atrial Fibrillation
SPORTIF Stroke Prevention using an Oral Direct Thrombin
Inhibitor In Patients with Atrial Fibrillation
SRAF subacute recurrence of atrial ﬁbrillation
STAF Strategies of Treatment of Atrial Fibrillation
SVC superior vena cava
TEE transesophageal echocardiography
TGF-beta1 transforming growth factor-beta1
TIA transient ischemic attack
TRACE Trandolapril Cardiac Evaluation
UK-TIA The United Kingdom transient ischaemic attack
aspirin trial
Val-HeFT Valsartan Heart Failure Trial
VF ventricular ﬁbrillation
WPW Wolff-Parkinson-White
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